Updated on 2025/07/09

All information, except for affiliations, is reprinted from the information registered on researchmap.

写真a

 
Yusuke Kobayashi
 
Organization
Yokohama City University Hospital YCU Center for Novel and Exploratory Clinical Trials Lecturer
Title
Lecturer
Profile

【研究テーマ】
「生体信号情報と分子生物学的情報の統合解析による血液透析患者・生活習慣病患者・健常者の倦怠感メカニズム解明」

「健康寿命延伸を目指した生活習慣病領域の分野横断的研究」
「セルフメディケーションのためのソリューション開発を目指した産学官連携共同研究」

「難培養微生物に着目した創薬プラットフォーム構築」

「腎疾患治療薬開発を目指す橋渡し研究」

「腸内細菌叢の改変による新たな認知症治療法開発」

「若者の生きづらさを解消し高いウェルビーイングを実現するメタケアシティ共創拠点　外部リソース獲得リーダー・産学連携リーダー」共創の場形成支援プログラム(COI-NEXT)」共創分野本格型

【所属学会・資格】
日本内科学会 総合内科専門医
日本腎臓学会 腎臓専門医
日本透析医学会 透析専門医
日本高血圧学会 高血圧専門医・指導医
国際高血圧学会 Emerging Leader
日本動脈硬化学会
日本自律神経学会
日本サルコペニア・フレイル学会

External link

Degree

  • 博士（医学） ( 横浜市立大学大学院 )

Research Interests

  • hemodialysis

  • セルフメディケーション

  • 健康寿命延伸

  • 在宅医療

  • fatigue

  • Well-being

  • 自律神経

  • 慢性腎臓病

  • フレイル

  • サルコペニア

  • 産学官民連携

  • 原発性アルドステロン症

  • 高血圧

  • 脂質異常症

  • 動脈硬化

  • レジリエンス

Research Areas

  • Life Science / Nephrology

Education

  • Yokohama City University   Graduate   Graduate School of Medicine

    2007 - 2011

    　 More details

  • Niigata University   Faculty of Medicine   School of Medicine

    - 2005

    　 More details

Research History

  • Yokohama City University   YCU Co-Creation Innovation Center   Vice Director・Lecturer

    2024.4

    　 More details

  • 横浜市立大学附属病院   次世代臨床研究センター 戦略相談室   室長/講師

    2022.4

    　 More details

  • 横浜市立大学附属病院 次世代臨床研究センター 戦略相談室 室長

    2021.7 - 2022.3

    　 More details

  • 横浜市立大学附属病院   次世代臨床研究センター 教育研修室   室長

    2020.4 - 2021.6

    　 More details

  • Yokohama City University   YCU Center for Novel and Exploratory Clinical Trials, Hospital   Assistant Professor

    2019.4 - 2022.3

    　 More details

  • 済生会横浜市南部病院   腎臓高血圧内科   医長

    2017 - 2019

    　 More details

  • イタリア パドヴァ大学   動脈高血圧部門   客員研究員

    2017

    　 More details

  • 横須賀市立市民病院   腎臓内科   主任医長

    2015 - 2017

    　 More details

  • Yokohama City University

    2013 - 2019

    　 More details

  • 横須賀市立市民病院   腎臓内科   医員

    2013 - 2015

    　 More details

  • Yokohama City University   Nephrology/Hypertension, Hospital   Assistant Professor

    2011 - 2013

    　 More details

  • Yokohama City University   Nephrology/Hypertension, Hospital

    2011

    　 More details

  • Yokohama City University   Medical Center, Devision of Nephrology and Hypertension

    2007 - 2008

    　 More details

  • Yokohama City University   Hospital

    2005 - 2007

    　 More details

▼display all

Professional Memberships

▼display all

Committee Memberships

  • 神奈川保険医協会   倫理審査委員会 委員  

    2018   

    　 More details

    Committee type：Academic society

    researchmap

Papers

  • Visualizing fatigue mechanisms in non-communicable diseases: an integrative approach with multi-omics and machine learning. International journal

    Yusuke Kobayashi, Naoki Fujiwara, Yuki Murakami, Shoichi Ishida, Sho Kinguchi, Tatsuya Haze, Kengo Azushima, Akira Fujiwara, Hiromichi Wakui, Masayoshi Sakakura, Kei Terayama, Nobuhito Hirawa, Tetsuo Isozaki, Hiroaki Yasuzaki, Hajime Takase, Yuichiro Yano, Kouichi Tamura

    BMC medical informatics and decision making   25 ( 1 )   204 - 204   2025.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Fatigue is a prevalent and debilitating symptom of non-communicable diseases (NCDs); however, its biological basis are not well-defined. This exploratory study aimed to identify key biological drivers of fatigue by integrating metabolomic, microbiome, and genetic data from blood and saliva samples using a multi-omics approach. METHODS: Metabolomic, microbiome, and single nucleotide polymorphisim analyses were conducted on saliva and blood samples from 52 patients with NCDs. Fatigue dimensions were assessed using the Multidimensional Fatigue Inventory and correlated with biological markers. LightGBM, a gradient boosting algorithm, was used for fatigue prediction, and model performance was evaluated using the F1-score, accuracy, and receiver operating characteristic area under the curve using leave-one-out cross-validation. Statistical analyses included correlation tests and multiple comparison adjustments (p < 0.05; false discovery rate <0.05). This study was approved by the Yokohama City University Hospital Ethics Committee (F230100022). RESULTS: Plasmalogen synthesis was significantly associated with physical fatigue in both blood and saliva samples. Additionally, homocysteine degradation and catecholamine biosynthesis in the blood were significantly associated with mental fatigue (Holm p < 0.05). Microbial imbalances, including reduced levels of Firmicutes negativicutes and Patescibacteria saccharimonadia, correlated with general and physical fatigue (r = - 0.379, p = 0.006). Genetic variants in genes, such as GPR180, NOTCH3, SVIL, HSD17B11, and PLXNA1, were linked to various fatigue dimensions (r range: -0.539-0.517, p < 0.05). Machine learning models based on blood and salivary biomarkers achieved an F1-score of approximately 0.7 in predicting fatigue dimensions. CONCLUSION: This study provides preliminary insights into the potential involvement of alterations in lipid metabolism, catecholamine biosynthesis disruptions, microbial imbalances, and specific genetic variants in fatigue in patients with NCDs. These findings lay the groundwork for personalized interventions, although further validation and model refinement across diverse populations are needed to enhance the prediction performance and clinical applicability.

    DOI： 10.1186/s12911-025-03034-3

    PubMed

    researchmap

  • Updated meta-analysis for antihypertensive treatment guided by home blood pressure compared to treatment based on office blood pressure: systematic review. International journal

    Tatsuya Maruhashi, Yukako Tatsumi, Michihiro Satoh, Yusuke Kobayashi, Yukako Ogoyama, Atsushi Sakima, Hisatomi Arima, Takayoshi Ohkubo

    Hypertension research : official journal of the Japanese Society of Hypertension   48 ( 6 )   1839 - 1845   2025.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Home blood pressure (BP) measurement is widely used, and home BP plays a central role in hypertension management in clinical practice in Japan. We updated the systematic review to determine whether home BP-based antihypertensive treatment is superior to office BP-based treatment in improving clinical outcomes, including BP levels, in adult patients with essential hypertension. A literature search identified 14 randomized controlled trials (RCTs). The results of meta-analysis revealed that home BP-based antihypertensive treatment was significantly associated with greater reductions in ambulatory systolic BP by 2.73 mmHg (95% confidence interval [CI], -5.23 to -2.22 mmHg; p = 0.03) and ambulatory diastolic BP by 1.61 mmHg (95% CI, -3.21 to -0.01 mmHg; p = 0.05) compared to office BP-based treatment. No RCTs evaluating cardiovascular outcomes other than ambulatory BP reduction were identified. Consistent with the previous review, this updated meta-analysis revealed home BP-based antihypertensive treatment is strongly recommended over office BP-based treatment for BP control in patients with essential hypertension.

    DOI： 10.1038/s41440-024-02072-0

    PubMed

    researchmap

  • Diverse Roles and Characteristics of Academic Research Organizations in Japan: Results of A Questionnaire-Based Study. International journal

    Reo Tanoshima, Riki Tanaka, Koji Hara, Hironori Fukuoka, Tatsuya Haze, Naoko Inagaki, Akifumi Ijuin, Manabu Nitta, Yusuke Kobayashi, Kozo Okada, Akito Nozaki, Etsuko Miyagi, Tetsuya Yamamoto, Takahisa Goto

    Therapeutic innovation & regulatory science   2025.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Clinical trials in Japan are governed by three regulations: Japanese Good Clinical Practice (J-GCP), the Clinical Trials Act, and the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. Academic research organizations (AROs) are non-profit entities established to support clinician-scientists in conducting rigorous and high-quality clinical trials. However, Japan's unique decentralized clinical trial system has resulted in relatively small AROs with diverse roles. Additionally, work style reforms among Japanese physicians pose challenges for allocating time to research. This study aimed to assess the demographics, activities, and roles of AROs in Japan. METHODS: We distributed a questionnaire survey to 31 AROs in Japan between October and December 2023. The survey collected data on organizational mission, vision, annual planning, clinical trial support, the number of supported studies, financial independence, and management of researchers' working hours. RESULTS: Responses were received from 20 AROs (64.5%), including five public university hospitals and two clinical research core hospitals. The median staff size was 26.7 (range: 2-80), with public university hospitals reporting a median of 22.6 (range: 1449). Y-NEXT had a larger staff size (53.4) compared with other public university hospitals but fewer than clinical research core hospitals (median: 78.5). Thirteen AROs (65.0%) reported having organizational missions, and 25.0% were financially independent. Effort allocation for staff varied among institutions, and six AROs (30.0%) managed researchers' working hours. CONCLUSION: The roles and ultimate goals of AROs vary across institutions, highlighting the need for alignment with each institution's clinical research priorities and principles.

    DOI： 10.1007/s43441-025-00797-9

    PubMed

    researchmap

  • Switching from ARBs to sacubitril/valsartan safely improves 24-hour ambulatory blood pressure in patients with advanced chronic kidney disease. International journal

    Sho Kinguchi, Kohei Ishiga, Hiromichi Wakui, Kengo Azushima, Tomohiko Kanaoka, Yusuke Kobayashi, Tatsuya Haze, Nobuhito Hirawa, Kouichi Tamura

    American journal of hypertension   38 ( 6 )   380 - 388   2025.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: We investigated the effects of sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), on 24-hour blood pressure (BP) and safety for 12 weeks in Japanese patients with non-dialysis advanced chronic kidney disease (CKD). METHODS: We conducted a prospective, single-arm exploratory study. Patients with non-dialysis CKD stage G4-5 (estimated glomerular filtration (eGFR) <30 mL/min/1.73 m2) who did not achieve their BP goals with angiotensin receptor blocker (ARB) administration, were enrolled and switched to sacubitril/valsartan. Primary and key secondary endpoints were changes from baseline in the 24-hour systolic BP (SBP) measured via ambulatory BP monitoring (ABPM) over 12 weeks and the safety, especially incidence of serum creatinine (Cr) increase (≥30% increase from baseline) and hyperkalemia. RESULTS: Thirty patients were enrolled, and 29 patients were switched to sacubitril/valsartan. Efficacy analysis was conducted on 26 patients. Baseline mean eGFR and office BP were 21.1±5.0 mL/min/1.73m2 and 149.4±23.7/80.7±11.9 mmHg, respectively. Baseline 24-hour, daytime, and nighttime BP were 139.6±17.7/77.0±7.8 mmHg, 143.5±18.5/79.6±8.7 mmHg, and 131.0±20.4/71.1±8.8 mmHg, respectively. After 12 weeks, changes in 24-hour, daytime, and nighttime SBP from baseline were -7.1±12.4 mmHg (P <0.01), -7.7±12.9 mmHg (P <0.01), and -5.8±15.8 mmHg (P = 0.07), respectively. No incidences of potassium values >6.0 mmol/L or serum Cr ≥30% increase from baseline were reported after sacubitril/valsartan initiation. CONCLUSIONS: Switching from ARB to sacubitril/valsartan can safely enhance 24-hour antihypertensive treatment in patients with non-dialysis CKD G4-5 who do not achieve BP goals with ARBs.CLINICAL TRIALS REGISTRATION: Trial Number jRCT1031220149.

    DOI： 10.1093/ajh/hpaf028

    PubMed

    researchmap

  • Oral microbiome alpha diversity and all-cause, cardiovascular, and non-cardiovascular mortality in US adults: Evidence from the NHANES 2009-2019. International journal

    Rajib Mondal, Rani Baroi Ritu, Kaori Kitaoka, Nazar Mohd Azahar, Mohammad Moniruzzaman, Soshiro Ogata, Eri Kiyoshige, Haruka Tohara, Yusuke Kobayashi, Naoki Kashihara, Toshio Naito, Naoki Nakashima, Kosuke Tamura, Kunihiro Nishimura, Anthony J Viera, Yuichiro Yano

    Atherosclerosis   401   119074 - 119074   2025.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND AND AIMS: Knowledge about the association between oral microbiome diversity within individuals and cardiovascular disease (CVD) and non-CVD mortality is scarce. Besides, variation by sex and racial and ethnic groups, and the potential mediators of these associations remain unclear. We aimed to investigate the associations of oral microbiome alpha diversity with all-cause, CVD, and non-CVD mortality, and the interaction effects of sex and racial and ethnic groups and potential mediators in the associations. METHODS: The National Health and Nutrition Examination Survey (NHANES) is a population-based observational study, conducted periodically in Mexican American, Other Hispanic, Non-Hispanic (NH) White, NH Black, and other racial/ethnic participants. We linked 2009-12 survey data of 8199 adults to the mortality data until 2019. By analyzing RNA gene sequences from oral rinse samples, microbiome alpha diversity within individuals was assessed using operational taxonomic unit (OTU) richness. Potential mediators included obesity, diabetes mellitus, dyslipidemia, hypertension, and periodontitis. Multivariable Cox proportional hazards regression and causal mediation analysis were used. RESULTS: Baseline mean ± standard deviation (SD) age was 42.1 ± 15.1 years. Over a median follow-up of 9.1 years, 405 all-cause mortality occurred (CVD, 105; non-CVD, 300). Each 1-SD increment in OTU richness was inversely associated with all-cause mortality (hazard ratio [HR] 0.92, 95 % confidence interval [CI] 0.90-0.95), CVD mortality (HR, 0.92; 95 % CI, 0.90-0.95), and non-CVD mortality (HR, 0.92; 95 % CI, 0.90-0.95). With evidence of significant racial and ethnic groups-interaction (p <0.05), these associations were evident in Mexican American, NH White, and others racial/ethnic participants. None of the potential mediators significantly mediated the associations of OTU richness with all-cause, CVD, and non-CVD mortality. CONCLUSIONS: Lower oral microbiome alpha diversity is associated with higher risk for all-cause, CVD, and non-CVD mortality, and the associations are varied by racial and ethnic groups.

    DOI： 10.1016/j.atherosclerosis.2024.119074

    PubMed

    researchmap

  • Using a Quality Management System and Risk-based Approach in Observational Studies to Obtain Robust Real-World Evidence. International journal

    Reo Tanoshima, Naoko Inagaki, Manabu Nitta, Soichiro Sue, Sayuri Shimizu, Tatsuya Haze, Kotaro Senuki, Chihiro Sano, Hajime Takase, Makoto Kaneko, Akito Nozaki, Kozo Okada, Kohei Ohyama, Atsushi Kawaguchi, Yusuke Kobayashi, Hideki Oi, Shin Maeda, Yuichiro Yano, Yuji Kumagai, Etsuko Miyagi

    Therapeutic innovation & regulatory science   58 ( 6 )   1006 - 1013   2024.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The results of observational studies using real-world data, known as real-world evidence, have gradually started to be used in drug development and decision-making by policymakers. A good quality management system-a comprehensive system of process, data, and documentation to ensure quality-is important in obtaining real-world evidence. A risk-based approach is a common quality management system used in interventional studies. We used a quality management system and risk-based approach in an observational study on a designated intractable disease. Our multidisciplinary team assessed the risks of the real-world data study comprehensively and systematically. When using real-world data and evidence to support regulatory decisions, both the quality of the database and the validity of the outcome are important. We followed the seven steps of the risk-based approach for both database selection and research planning. We scored the risk of two candidate databases and chose the Japanese National Database of designated intractable diseases for this study. We also conducted a quantitative assessment of risks associated with research planning. After prioritizing the risks, we revised the research plan and outcomes to reflect the risk-based approach. We concluded that implementing a risk-based approach is feasible for an observational study using real-world data. Evaluating both database selection and research planning is important. A risk-based approach can be essential to obtain robust real-world evidence.

    DOI： 10.1007/s43441-024-00695-6

    PubMed

    researchmap

  • Clinical Utility of Machine Learning-Derived Vocal Biomarkers in the Management of Heart Failure.

    Kozo Okada, Daisuke Mizuguchi, Yasuhiro Omiya, Koji Endo, Yusuke Kobayashi, Noriaki Iwahashi, Masami Kosuge, Toshiaki Ebina, Kouichi Tamura, Teruyasu Sugano, Tomoaki Ishigami, Kazuo Kimura, Kiyoshi Hibi

    Circulation reports   6 ( 8 )   303 - 312   2024.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: This study aimed to systematically evaluate voice symptoms during heart failure (HF) treatments and to exploratorily extract HF-related vocal biomarkers. METHODS AND RESULTS: This single-center, prospective study longitudinally acquired 839 audio files from 59 patients with acute decompensated HF. Patients' voices were analyzed along with conventional HF indicators (New York Heart Association [NYHA] class, presence of pulmonary congestion and pleural effusion on chest X-ray, and B-type natriuretic peptide [BNP]) and GOKAN scores based on the assessment of a cardiologist. Machine-learning (ML) models to estimate HF conditions were created using a Light Gradient Boosting Machine. Voice analysis identified 27 acoustic features that correlated with conventional HF indicators and GOKAN scores. When creating ML models based on the acoustic features, there was a significant correlation between actual and ML-derived BNP levels (r=0.49; P<0.001). ML models also identified good diagnostic accuracies in determining HF conditions characterized by NYHA class ≥2, BNP ≥300 pg/mL, presence of pulmonary congestion or pleural effusion on chest X-ray, and decompensated HF (defined as NYHA class ≥2 and BNP levels ≥300 pg/mL; accuracy: 75.1%, 69.1%, 68.7%, 66.4%, and 80.4%, respectively). CONCLUSIONS: The present study successfully extracted HF-related acoustic features that correlated with conventional HF indicators. Although the data are preliminary, ML models based on acoustic features (vocal biomarkers) have the potential to infer various HF conditions, which warrant future studies.

    DOI： 10.1253/circrep.CR-24-0064

    PubMed

    researchmap

  • Effectiveness of digital health interventions for telemedicine/telehealth for managing blood pressure in adults: a systematic review and meta-analysis. International journal

    Atsushi Sakima, Yuya Akagi, Yuichi Akasaki, Takako Fujii, Tatsuya Haze, Fumiko Kawakami-Mori, Ken Kitajima, Yusuke Kobayashi, Tetsutaro Matayoshi, Takashi Sakaguchi, Masanobu Yamazato, Makiko Abe, Yusuke Ohya, Hisatomi Arima

    Hypertension research : official journal of the Japanese Society of Hypertension   48 ( 2 )   478 - 491   2024.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    This systematic review and meta-analysis included randomized controlled trials or observational studies that compare digital health interventions (DHIs) for telemedicine/telehealth versus usual care for managing blood pressure (BP) in adults. We searched PubMed, Cochrane CENTRAL, and IchuShi-Web, and used a random-effects meta-analysis of the weighted mean difference (MD) between the comparison groups to pool data from the included studies. The outcome included the pooled MD of office BP from baseline to each follow-up period. This meta-analysis considered 117 studies with 68677 participants as eligible. The 3-month intervention period reduced office systolic BP (SBP) compared with usual care in 38 studies (MD: -3.21 mmHg [95% confidence interval: -4.51 to -1.90]), with evidence of heterogeneity. Office SBP across intervention periods demonstrated comparable effects (3-, 6- [54 studies], 12- [43 studies], and >12-month periods [9 studies]). The benefits for office diastolic BP were similar to those for office SBP. Additionally, the interventions significantly reduced the office SBP compared with the control, regardless of the mode of intervention delivery (smartphone apps [38 studies], text messages [35 studies], and websites [34 studies]) or type of facility (medical [74 studies] vs. non-medical [33 studies]). The interventions were more effective in 41 hypertension cohorts compared with 66 non-hypertension cohorts (-4.81 mmHg [-6.33, -3.29] vs. -2.17 mmHg [-3.15, -1.19], P = 0.006 for heterogeneity). In conclusion, DHIs for telemedicine/telehealth improved BP management compared with usual care. The effectiveness with heterogeneity should be considered, as prudent for implementing evidence-based medicine. This meta-analysis considered 117 studies with 68677 participants eligible. The DHIs for telemedicine/telehealth reduced office BP compared with usual care, regardless of intervention duration, intervention delivery mode, facility type, and cohort type. Additionally, the DHIs reduced the risk of uncontrolled BP compared with usual care, regardless of intervention duration, intervention delivery mode, and facility type. BP blood pressure, DHI digital health intervention, MD mean difference, RR risk ratio, SBP systolic blood pressure.

    DOI： 10.1038/s41440-024-01792-7

    PubMed

    researchmap

  • Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip.

    Rina Kawano, Tatsuya Haze, Akira Fujiwara, Aiko Haruna, Moe Ozawa, Yusuke Kobayashi, Sanae Saka, Nobuhito Hirawa, Kouichi Tamura

    Clinical and experimental nephrology   28 ( 12 )   1282 - 1289   2024.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Renoprotective effects of sodium glucose transporter 2 (SGLT2) inhibitors, including dapagliflozin, were observed in randomized controlled trials (RCTs). The suspected underlying mechanism is a correction of hyperfiltration, observed as an "initial dip". Whether SGLT2 inhibitors can attenuate the rate of decline in the estimated glomerular filtration rate (eGFR) in clinical settings, even when considering the pre-treatment decline rate, is unknown. Although several RCTs identified an association between the initial dip and long-term renal prognoses, a conclusion has not been reached. METHODS: We collected the eGFR data of patients for whom dapagliflozin was initiated in our hospital and then calculated their eGFR slopes before and after the start of the treatment. We investigated the changes in the eGFR slopes (ΔeGFR slope) and the association between the ΔeGFR slope and the initial dip. Risks for rapid eGFR decliners (eGFR slope < - 3 mL/min/1.73 m2/year) were also examined. RESULTS: The eGFR slope was significantly milder after dapagliflozin treatment (p < 0.01). A deeper initial dip was associated with a milder rate of eGFR decline (adjusted beta: - 0.29, p < 0.001). Dapagliflozin treatment reduced the proportion of rapid eGFR decliners from 52.9 to 14.7%, and a smaller initial dip was identified as a significant risk for post-treatment rapid eGFR decline (adjusted odds ratio: 1.73, p < 0.05). CONCLUSIONS: Compared to before the administration of dapagliflozin, the rate of eGFR decline was significantly milder after its administration. The initial dip was significantly associated with long-term renoprotective effects and may be a useful predictor of treatment response.

    DOI： 10.1007/s10157-024-02532-4

    PubMed

    researchmap

  • ATP2B1 gene polymorphisms associated with resistant hypertension in the Japanese population International journal

    Yusuke Kobayashi, Keisuke Yatsu, Aiko Haruna, Rina Kawano, Moe Ozawa, Tatsuya Haze, Shiro Komiya, Shota Suzuki, Yuki Ohki, Akira Fujiwara, Sanae Saka, Nobuhito Hirawa, Yoshiyuki Toya, Kouichi Tamura

    The Journal of Clinical Hypertension   26 ( 4 )   355 - 362   2024.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Single-nucleotide polymorphisms (SNP) of ATP2B1 gene are associated with essential hypertension but their association with resistant hypertension (RHT) remains unexplored. The authors examined the relationship between ATP2B1 SNPs and RHT by genotyping 12 SNPs in ATP2B1 gene of 1124 Japanese individuals with lifestyle-related diseases. Patients with RHT had inadequate blood pressure (BP) control using three antihypertensive drugs or used ≥4 antihypertensive drugs. Patients with controlled hypertension had BP controlled using ≤3 antihypertensive drugs. The association between each SNP and RHT was analyzed by logistic regression. The final cohort had 888 (79.0%) and 43 (3.8%) patients with controlled hypertension and RHT, respectively. Compared with patients homozygous for the minor allele of each SNP in ATP2B1, a significantly higher number of patients carrying the major allele at 10 SNPs exhibited RHT (most significant at rs1401982: 5.8% vs. 0.8%, p = .014; least significant at rs11105378: 5.7% vs. 0.9%, p = .035; most nonsignificant at rs12817819: 5.1% vs. 10%, p = .413). After multivariate adjustment for age, sex, systolic BP, and other confounders, the association remained significant for rs2681472 and rs1401982 (OR: 7.60, p < .05 and OR: 7.62, p = .049, respectively). Additionally, rs2681472 and rs1401982 were in linkage disequilibrium with rs11105378. This study identified two ATP2B1 SNPs associated with RHT in the Japanese population. rs1401982 was most closely associated with RHT, and major allele carriers of rs1401982 required significantly more antihypertensive medications. Analysis of ATP2B1 SNPs in patients with hypertension can help in early prediction of RHT and identification of high-risk patients who are more likely to require more antihypertensive medications.

    DOI： 10.1111/jch.14785

    PubMed

    researchmap

  • Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle–Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study International journal

    Yusuke Kobayashi, Tetsuya Fujikawa, Aiko Haruna, Rina Kawano, Moe Ozawa, Tatsuya Haze, Shiro Komiya, Shota Suzuki, Yuki Ohki, Akira Fujiwara, Sanae Saka, Nobuhito Hirawa, Yoshiyuki Toya, Kouichi Tamura

    Medicina   60 ( 1 )   2023.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Background and Objectives: Omega-3 fatty acids have potent lipid-lowering and antiplatelet effects; however, randomized controlled trials have yet to examine the effect of high-dose omega-3 fatty acid administration on peripheral artery disease (PAD) in hemodialysis patients with dyslipidemia. Therefore, this study aimed to evaluate the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the ankle-brachial index (ABI) and remnant-like lipoprotein cholesterol (RLP-C) levels, which are indicators of PAD severity. Materials and Methods: Thirty-eight participants (mean age: 73.6 ± 12.7 years) were randomly assigned using stratified block randomization to either conventional therapy alone or conventional therapy supplemented with high-dose EPA/DHA (EPA: 1860 mg; DHA: 1500 mg) for a three-month intervention period. Patients in the conventional therapy alone group who opted to continue were provided with a low-dose EPA/DHA regimen (EPA: 930 mg; DHA: 750 mg) for an additional three months. The baseline and 3-month values for RLP-C, an atherogenic lipid parameter, and the ABI were recorded. Results: The results of the 3-month assessments revealed that the mean RLP-C changes were -3.25 ± 3.15 mg/dL and 0.44 ± 2.53 mg/dL in the EPA/DHA and control groups, respectively (p < 0.001), whereas the changes in the mean ABI values were 0.07 ± 0.11 and -0.02 ± 0.09 in the EPA/DHA and control groups, respectively (p = 0.007). In the EPA/DHA group, a significant negative correlation was found between the changes in RLP-C levels and the ABI (r = -0.475, p = 0.04). Additionally, the change in the RLP-C levels independently influenced the change in the ABI in the EPA/DHA group, even after adjusting for age, sex, and statin use (p = 0.042). Conclusions: Add-on EPA/DHA treatment improved the effectiveness of conventional therapy (such as statin treatment) for improving the ABI in hemodialysis patients with dyslipidemia by lowering RLP-C levels. Therefore, clinicians involved in dialysis should focus on RLP-C when considering residual cardiovascular disease risk in hemodialysis patients and should consider screening patients with elevated levels.

    DOI： 10.3390/medicina60010075

    PubMed

    researchmap

  • RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia. International journal

    Teresa Maria Seccia, Tungalagtamir Shagjaa, Margherita Morpurgo, Brasilina Caroccia, Viola Sanga, Sonia Faoro, Francesca Venturini, Girolama Iadicicco, Sara Lococo, Maria Mazzitelli, Filippo Farnia, Paola Fioretto, Yusuke Kobayashi, Dario Gregori, Gian Paolo Rossi

    Journal of clinical medicine   12 ( 20 )   2023.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection. The goal of the RAndomized Clinical Trial Of NAfamostat (RACONA) study, designed as a prospective randomized, double-blind placebo-controlled clinical trial, was to investigate the efficacy and safety of nafamostat mesylate (0.10 mg/kg/h iv for 7 days), on top of the optimal treatment, in COVID-19 hospitalized patients. We could screen 131 patients, but due to the predefined strict inclusion and exclusion criteria, only 15 could be randomized to group 1 (n = 7) or group 2 (n = 8). The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. No adverse events, including hyperkalemia, were found to be associated with nafamostat. Thus, the RACONA study showed a good safety profile of nafamostat, suggesting that it could be usefully used in COVID-19 hospitalized patients.

    DOI： 10.3390/jcm12206618

    PubMed

    researchmap

  • Influence of Functional Impairment on Prognosis in Hospitalized Elderly Patients on Dialysis.

    Kouichi Tamura, Yu Soma, Tatsuya Haze, Yusuke Kobayashi

    JMA journal   6 ( 4 )   414 - 415   2023.10

    　More details

  • Renin-angiotensin-aldosterone system inhibitors as a risk factor for chronic subdural hematoma recurrence: A matter of debate. International journal

    Wataru Shimohigoshi, Hajime Takase, Tatsuya Haze, Yusuke Kobayashi, Hiroshi Manaka, Takashi Kawasaki, Katsumi Sakata, Tetsuya Yamamoto

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association   32 ( 10 )   107291 - 107291   2023.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVES: Chronic subdural hematoma (cSDH) is a common central nervous system condition. Recent reports indicate that cSDH affects long-term prognosis; however, its definitive risk factors remain unknown. An antihypertensive drug, renin-angiotensin-aldosterone system inhibitors (RAASi), can affect vascular permeability and cell proliferation processes, which may suppress the recurrence of cSDH. However, several studies have reported negative results to this effect. Therefore, we aimed to evaluate antihypertensive drugs, including RAASi, as risk factors for recurrent cSDH. MATERIALS AND METHODS: A total of 203 consecutive cases of surgically treated cSDH were retrospectively reviewed. Clinical and radiological parameters were compared between the groups with and without cSDH recurrence to identify risk factors. RESULTS: Of the included cases, 68 (33.5%) used RAASi and 37 (18.2%) developed recurrence within 60 days of surgery. In the multiple logistic regression analysis adjusted by composite risk score, the odds ratios (95% confidence interval) of RAASi, calcium channel blockers, diuretics, β and α blockers, for the recurrent risk of cSDH after surgery were 2.49 (1.16, 5.42), 1.79 (0.84, 3.82), 1.83 (0.62, 4.87), 0.90 (0.28, 2.44), and 0.96 (0.21, 3.20), respectively. The Cox proportional hazard model also demonstrated that RAASi-use was an independent risk factor for cSDH recurrence. CONCLUSIONS: Present series suggests RAASi-use as a risk factor for cSDH recurrence, although the role of RAASi-use in cSDH remains debatable. Further studies for deeper understanding of the microenvironment of hematoma and the surroundings are preferable. (235 words).

    DOI： 10.1016/j.jstrokecerebrovasdis.2023.107291

    PubMed

    researchmap

  • African Control of Hypertension through Innovative Epidemiology and a Vibrant Ecosystem (ACHIEVE): a holistic approach for hypertension control in Africa. International journal

    Nomin Bayaraa, Nazar Mohd Azahar, Kaori Kitaoka, Yusuke Kobayashi, Yuichiro Yano

    Journal of human hypertension   2023.6

    　More details

  • Effect of the interaction between the visceral-to-subcutaneous fat ratio and aldosterone on cardiac function in patients with primary aldosteronism International journal

    Tatsuya Haze, Moe Ozawa, Rina Kawano, Aiko Haruna, Yuki Ohki, Shota Suzuki, Yusuke Kobayashi, Akira Fujiwara, Sanae Saka, Kouichi Tamura, Nobuhito Hirawa

    HYPERTENSION RESEARCH   46 ( 5 )   1132 - 1144   2023.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41440-023-01170-9

    Web of Science

    PubMed

    researchmap

  • The implication of calf circumference and grip strength in osteoporosis and bone mineral density among hemodialysis patients

    Moe Ozawa, Nobuhito Hirawa, Tatsuya Haze, Aiko Haruna, Rina Kawano, Shiro Komiya, Yuki Ohki, Shota Suzuki, Yusuke Kobayashi, Akira Fujiwara, Sanae Saka, Masaaki Hanaoka, Hiroshi Mitsuhashi, Satoshi Yamaguchi, Toshimasa Ohnishi, Kouichi Tamura

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   27 ( 4 )   365 - 373   2023.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10157-022-02308-8

    Web of Science

    PubMed

    researchmap

  • White-coat effect on orthostatic hypotension: a nationwide survey of Japanese general practitioners. International journal

    Shohei Yuasa, Hareaki Yamamoto, Yoshiro Suzuki, Keiichi Chin, Hiroshi Ukai, Yusuke Kobayashi, Yuichiro Yano, Hisao Mori

    Blood pressure monitoring   27 ( 5 )   314 - 319   2022.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    OBJECTIVE: The relationship between the white-coat effect (WCE), defined as white-coat hypertension under treatment, and the frequency of orthostatic hypotension (OH) is not known. We conducted an orthostatic test in patients with WCE to determine the frequency of OH. METHODS: This was a cross-sectional study of 5631 patients with hypertension visiting general practitioners nationwide, in which 4305 patients with hypertension recorded their home blood pressure (BP) and consented to the orthostatic test. Patients with hypertension were divided into four groups: controlled hypertension (CHT), masked hypertension (MHT), sustained hypertension (SHT), and WCE. The orthostatic test was performed, and BP and pulse rate were measured immediately and 1 min after orthostasis. RESULTS: The OH frequencies immediately after standing in CHT, WCE, SHT, and MHT patients were 7, 11.7, 12.1, and 6.6%, respectively, and those at 1 min after standing were 7.1, 13.1, 11.6 and 6.9%, respectively (Chi-square test, P < 0.01, respectively). Logistic regression analysis was performed to examine the relationship between WCE and the frequency of OH. The frequency of OH immediately after standing was significantly increased [adjusted odds ratio (AOR), 1.702; 95% confidence interval (CI), 1.246-2.326; P < 0.01]. The frequency of OH at 1 min after standing was also significantly higher (AOR, 1.897; 95% CI, 1.396-2.578; P < 0.01). CONCLUSION: When the standing test was performed for patients with WCE, the frequency of OH increased. Thus, it is important to recognize the possibility of OH in patients with WCE to avoid adverse events associated with excessive hypotension.

    DOI： 10.1097/MBP.0000000000000605

    PubMed

    researchmap

  • Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.

    Shiro Komiya, Mari Katsumata, Moe Ozawa, Tatsuya Haze, Rina Kawano, Yuki Ohki, Shota Suzuki, Yusuke Kobayashi, Akira Fujiwara, Sanae Saka, Kouichi Tamura, Nobuhito Hirawa

    Clinical and experimental nephrology   26 ( 9 )   851 - 858   2022.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Tolvaptan (TLV) is reported to improve diuretic effects in patients with chronic kidney disease (CKD) when furosemide (FUR) is not sufficiently effective. However, it is not clear whether TLV addition is effective for advanced CKD patients with heart failure. METHODS: An open-label, parallel-group randomized trial was performed. The subjects were 33 patients with CKD stage G3-G5 who had fluid overload despite taking 20-100 mg/day FUR. They were divided into two groups: a group administered 15 mg/day TLV plus their original FUR dose for 7 days (TLV group), and a group administered 120-200 mg/day FUR (i.e., 100 mg/day over their previous dose) for 7 days (FUR group). RESULTS: The mean change in urine volume was significantly higher in the TLV group compared to the FUR group (637 ml vs 119 ml; p < 0.05). The difference was greater when the urine osmolality before treatment was high. Serum creatinine was increased only in the FUR group. The incidence of worsening renal function (WRF) was significantly lower in the TLV group (18.8% vs 58.8%; p < 0.05). Serum sodium decreased significantly in the FUR group, but did not change in the TLV group. CONCLUSIONS: In patients with advanced CKD with fluid overload, the addition of TLV achieved a significantly higher urine volume with less adverse effects on renal function compared with increasing the dose of FUR. The efficacy and safety of TLV were higher in patients who had higher urine osmolality and lower serum sodium before treatment. CLINICAL TRIAL REGISTRATION: UMIN000014763.

    DOI： 10.1007/s10157-022-02224-x

    PubMed

    researchmap

  • Novel Capped-Needle Device: A Novel Safety Feature to Eliminate Air Bubbles in Hemodialysis. International journal

    Kazuhiko Shibata, Takahiro Shinzato, Shigeki Toma, Shigeru Nakai, Yusuke Kobayashi, Tatsuo Hashimoto, Koichi Tamura

    Blood purification   1 - 6   2022.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: Air bubbles in the dialysis circuit are rarely visible after automatic priming; however, they are often visible after the needles are manually connected to the circuit. To prevent this issue, we thought to prime needles with a circuit at automatic priming by the hemodialysis machine. In order to achieve this idea, we designed and manufactured a novel capped needle to connect the needles to the extracorporeal circuit before the automatic priming of the hemodialysis machine. This study investigated the effectiveness of this novel capped needle and compared it with the conventional method for preventing air bubble contamination. METHODS: We tested novel capped needles ten times to evaluate whether the dialysis machine works appropriately and removes air bubbles even with the attached capped needle. Next, we performed 25 trials using the conventional method, in which skilled nurses manually connect the needle. In both methods, we thoroughly counted the air bubbles with our naked eyes. We predicted that the capped needle would leave few bubbles in the circuit. In order to evaluate fewer bubbles, we conducted an additional experiment using a microparticle counter to measure the size and number of the bubbles. RESULTS: We thoroughly searched for air bubbles during each of the ten tests but could not find any bubbles visible to the naked eye. In the conventional method, bubbles were visible in 29 out of 50 cases. The bubble count was significantly lower in the capped-needle method than in the conventional method (p < 0.0001, Pearson's χ2 test). In the additional experiments using the microparticle counter, the average remaining air volume in the extracorporeal circuit was 0.0999 ± 0.2438 nL when the priming was performed using the novel capped needles. CONCLUSION: The novel capped needle eliminated all visible bubbles efficiently and effectively; therefore, it could be a valuable device for hemodialysis treatment. The reduction of air from the dialysis circuit may improve patient prognosis.

    DOI： 10.1159/000524357

    PubMed

    researchmap

  • Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease International journal

    Sho Kinguchi, Hiromichi Wakui, Yuzuru Ito, Yoshinobu Kondo, Kengo Azushima, Uru Osada, Tadashi Yamakawa, Tamio Iwamoto, Jun Yutoh, Toshihiro Misumi, Gen Yasuda, Taishi Yoshii, Kotaro Haruhara, Yusuke Kobayashi, Takeharu Yamanaka, Yasuo Terauchi, Kouichi Tamura

    Scientific Reports   11 ( 1 )   951 - 951   2021.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    <title>Abstract</title>We investigated the impact of basal dietary sodium intake on the dapagliflozin-induced changes in albuminuria and blood pressure (BP) measured at home in patients with diabetic kidney disease (DKD).This was a secondary analysis of the Y-AIDA Study, in which DKD patients with estimated glomerular filtration rate (eGFR) ≥ 45 ml/min/1.73 m<sup>2</sup> and urinary albumin-to-creatinine ratio (UACR) ≥ 30 mg/g creatinine were administered dapagliflozin for 24 weeks, and dapagliflozin significantly improved albuminuria levels and home BP profiles. The effects on UACR, home-measured BP, and eGFR were compared between high- and low-sodium intake groups (HS and LS groups), which were created using baseline urinary sodium-to-creatinine ratio of 84 participants with available basal sodium-to-creatinine ratios. At baseline, clinic-/home-measured BPs, UACR, and eGFR, were comparable in the two groups. After 24 weeks, the reductions from baseline in ln-UACR were comparable in the two groups. In contrast, the reductions in evening home systolic BP and eGFR from baseline were larger in HS than in LS (BP: − 13 ± 2.08 vs. − 6 ± 1.88, <italic>P</italic> = 0.020; eGFR: − 3.33 ± 1.32 vs. 0.37 ± 1.29, <italic>P</italic> = 0.049). The home BP-lowering effects of dapagliflozin are larger in HS than LS, concomitant with a larger reduction in eGFR, suggesting a dapagliflozin-induced improvement in glomerular relative hyperfiltration in HS.

    DOI： 10.1038/s41598-020-79687-z

    PubMed

    researchmap

    Other Link： http://www.nature.com/articles/s41598-020-79687-z

  • LPIN1 is a new target gene for essential hypertension. International journal

    Akira Fujiwara, Moe Ozawa, Koichiro Sumida, Nobuhito Hirawa, Keisuke Yatsu, Nao Ichihara, Tatsuya Haze, Shiro Komiya, Yuki Ohki, Yusuke Kobayashi, Hiromichi Wakui, Kouichi Tamura

    Journal of hypertension   40 ( 3 )   536 - 543   2021.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: We previously showed Lipin1 (LPIN1) to be a candidate gene for essential hypertension by genome-wide association studies. LPIN1 encodes the Lipin 1 protein, which contributes to the maintenance of lipid metabolism and glucose homeostasis. However, little is known about the association between LPIN1 and blood pressure (BP). METHODS: We evaluated the BP of LPIN1-deficient [fatty liver dystrophy (fld)] mice and explored related mechanisms. RESULTS: Fld mice have very low expression of LPIN1 and exhibit fatty liver, hypertriglyceridemia, insulin resistance and peripheral neuropathy. Fld mice had significantly elevated SBP and heart rate (HR) throughout the day as measured by a radiotelemetric method. Diurnal variation of SBP and HR was also absent in fld mice. Furthermore, urinary excretion of adrenaline and noradrenaline by fld mice was significantly higher compared with that of control mice. The BP response of fld mice to clonidine (a centrally acting α2-adrenergic receptor agonist) was greater than that of control mice. However, levels of Angiotensinogen and Renin 1 mRNA and urinary nitric oxide excretion were comparable between the two groups. The decrease in SBP at 8 weeks after fat grafting surgery was significantly greater in the transplant group compared with the sham operated group. CONCLUSION: The elevated BP in fld mice may result from activation of the sympathetic nervous system through decreased levels of adipose cytokines. These results indicate that LPIN1 plays a crucial role in blood pressure regulation and that LPIN1 is a new target gene for essential hypertension.

    DOI： 10.1097/HJH.0000000000003046

    PubMed

    researchmap

  • Association of the ratio of visceral-to-subcutaneous fat volume with renal function among patients with primary aldosteronism. International journal

    Tatsuya Haze, Moe Hatakeyama, Shiro Komiya, Rina Kawano, Yuki Ohki, Shota Suzuki, Yusuke Kobayashi, Akira Fujiwara, Sanae Saka, Kouichi Tamura, Nobuhito Hirawa

    Hypertension research : official journal of the Japanese Society of Hypertension   44 ( 10 )   1341 - 1351   2021.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Patients with primary aldosteronism have a higher risk of chronic kidney disease. Visceral fat tissue is hypothesized to stimulate the adrenal glands to overproduce aldosterone, and aldosterone promotes visceral fat tissue to produce inflammatory cytokines. However, it is unclear whether the volume of accumulated visceral fat tissue is associated with renal impairment among patients with hyperaldosteronism. We conducted a single-center cross-sectional study to assess the association between the estimated glomerular filtration rate and the ratio of the visceral-to-subcutaneous fat volume calculated by computed tomography. One hundred eighty patients with primary aldosteronism were enrolled. The mean ± SD age was 52.7 ± 11.0 years, and 60.0% were women. The ratio of visceral-to-subcutaneous fat volume was highly correlated with the estimated glomerular filtration rate (r = 0.49, p < 0.001). In multiple linear regression models, the ratio of visceral-to-subcutaneous fat tissue volume was significantly associated with the estimated glomerular filtration rate (estimates: -4.56 mL/min/1.73 m² per 1-SD), and there was an interaction effect between the plasma aldosterone concentration and the ratio of visceral-to-subcutaneous fat volume (p < 0.05). The group with a higher plasma aldosterone concentration exhibited a steeper decline in eGFR than the lower plasma aldosterone concentration group when the ratio increased. The ratio of visceral-to-subcutaneous fat tissue volume was an independent risk factor for renal dysfunction. This association increased in the presence of a high plasma aldosterone concentration. Clinicians should pay attention to the ratio of visceral-to-subcutaneous fat tissue volume and encourage primary aldosteronism patients to improve their lifestyle in addition to treating renin-aldosterone activity.

    DOI： 10.1038/s41440-021-00719-w

    PubMed

    researchmap

  • Associations Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism. Reviewed International journal

    Yusuke Kobayashi, Tatsuya Haze, Yuichiro Yano, Kouichi Tamura, Isao Kurihara, Takamasa Ichijo, Takashi Yoneda, Takuyuki Katabami, Mika Tsuiki, Norio Wada, Yoshihiro Ogawa, Junji Kawashima, Masakatsu Sone, Nobuya Inagaki, Tetsuya Yamada, Ryuji Okamoto, Megumi Fujita, Kohei Kamemura, Koichi Yamamoto, Shoichiro Izawa, Akiyo Tanabe, Mitsuhide Naruse

    Kidney international reports   5 ( 8 )   1291 - 1297   2020.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Introduction: Greater reduction in estimated glomerular filtration rate (eGFR) after specific treatment for primary aldosteronism (PA) reflects improvement in glomerular hyperfiltration associated with PA and leads to better patient outcomes. However, little is known regarding the mechanisms underlying eGFR reduction after treatment for PA. Methods: We analyzed data from the nationwide PA registry in Japan. Patients were assigned to adrenalectomy (n = 438) and mineralocorticoid receptor (MR) antagonist (n = 746) groups. We assessed associations between changes in blood pressure (BP), plasma renin activity (PRA) and plasma aldosterone concentrations (PAC), and eGFR before and 6 months after treatment for both groups. Results: In a multivariable linear regression, the adjusted β values (95% confidence interval [CI]) for change in eGFR after treatment were -2.76 (-4.29, -1.22) ml/min per 1.73 m2 for PRA (per 3.2 ng/ml per hour), and 1.97 (1.08, 2.85) ml/min per 1.73 m2 for PAC (per 236.1 pg/ml) in the adrenalectomy group; and -0.45 (-0.89, -0.01) ml/min per 1.73 m2 for PRA and -0.72 (-1.62, 0.18) ml/min per 1.73 m2 for PAC in the MR antagonist group. Change in mean arterial pressure after treatment was not significantly associated with change in eGFR in either group. Changes in PRA and PAC but not BP before and 6 months after treatment for PA were associated with greater reductions in eGFR. Conclusion: Post-treatment improvements in glomerular hyperfiltration may be attributable to decreased MR activity in the kidneys, but not to reductions in systemic BP.

    DOI： 10.1016/j.ekir.2020.06.012

    PubMed

    researchmap

  • Association of arterial stiffness with kidney function among adults without chronic kidney disease. Reviewed International journal

    Seiji Itano, Yuichiro Yano, Hajime Nagasu, Hirofumi Tomiyama, Hiroshi Kanegae, Hirofumi Makino, Yukihito Higashi, Yusuke Kobayashi, Yuji Sogawa, Minoru Satoh, Kenji Suzuki, Raymond R Townsend, Matthew Budoff, George Bakris, Naoki Kashihara

    American journal of hypertension   33 ( 11 )   1003 - 1010   2020.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Our aims were to assess whether arterial stiffness is associated with a higher risk for kidney dysfunction among persons without chronic kidney disease (CKD). METHODS: We analyzed data from the national health check-up system in Japan; for our analyses, we selected records of individuals who completed assessments of cardio-ankle vascular index (CAVI) and kidney function from 2005 to 2016. We excluded participants who had CKD at baseline, defined as the presence of proteinuria or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2. We compared two groups of CAVI measurements-the highest quartile (≧8.1) and the combined lower three quartiles (<8.1). We used Cox proportional hazards models to assess associations between these two groups and subsequent CKD events, proteinuria, eGFR <60 mL/min/1.73m2, and rapid eGFR decline (greater than or equal to -3 mL/min /1.73m2/year). RESULTS: The mean age of the 24,297 included participants was 46.2 years, and 60% were female. Over a mean follow-up of 3.1 years, 1,435 CKD events occurred. In a multivariable analysis, the hazard ratios (HRs) with 95% confidence intervals (CIs) for the highest versus combined lower quartiles of CAVI measurements were 1.3 (1.1,1.5) for CKD events, 1.3 (0.96,1.62) for proteinuria, 1.4 (1.1,1.7) for eGFR <60 mL/min/1.73m2, and the odds ratio with 95% CI was 1.3 (1.1,1.4) for rapid eGFR decline. CONCLUSION: Persons with CAVI measurements ≧8.1 had a higher risk for CKD events compared to their counterparts with CAVI measurements <8.1. Greater arterial stiffness among adults without CKD may be associated with kidney dysfunction.

    DOI： 10.1093/ajh/hpaa097

    PubMed

    researchmap

  • Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Reviewed International journal

    Sho Kinguchi, Hiromichi Wakui, Yuzuru Ito, Yoshinobu Kondo, Kengo Azushima, Uru Osada, Tadashi Yamakawa, Tamio Iwamoto, Jun Yutoh, Toshihiro Misumi, Kazutaka Aoki, Gen Yasuda, Taishi Yoshii, Takayuki Yamada, Syuji Ono, Tomoko Shibasaki-Kurita, Saho Hosokawa, Kazuki Orime, Masaaki Hanaoka, Hiroto Sasaki, Kohji Inazumi, Taku Yamada, Ryu Kobayashi, Kohji Ohki, Kotaro Haruhara, Yusuke Kobayashi, Takeharu Yamanaka, Yasuo Terauchi, Kouichi Tamura

    Cardiovascular diabetology   18 ( 1 )   110 - 110   2019.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: The Y-AIDA study was designed to investigate the renal- and home blood pressure (BP)-modulating effects of add-on dapagliflozin treatment in Japanese individuals with type 2 diabetes mellitus (T2DM) and albuminuria. METHODS: We conducted a prospective, multicenter, single-arm study. Eighty-six patients with T2DM, HbA1c 7.0-10.0%, estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2, and urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g creatinine (gCr) were enrolled, and 85 of these patients were administered add-on dapagliflozin for 24 weeks. The primary and key secondary endpoints were change from baseline in the natural logarithm of UACR over 24 weeks and change in home BP profile at week 24. RESULTS: Baseline median UACR was 181.5 mg/gCr (interquartile range 47.85, 638.0). Baseline morning, evening, and nocturnal home systolic/diastolic BP was 137.6/82.7 mmHg, 136.1/79.3 mmHg, and 125.4/74.1 mmHg, respectively. After 24 weeks, the logarithm of UACR decreased by 0.37 ± 0.73 (P < 0.001). In addition, changes in morning, evening, and nocturnal home BP from baseline were as follows: morning systolic/diastolic BP - 8.32 ± 11.42/- 4.18 ± 5.91 mmHg (both P < 0.001), evening systolic/diastolic BP - 9.57 ± 12.08/- 4.48 ± 6.45 mmHg (both P < 0.001), and nocturnal systolic/diastolic BP - 2.38 ± 7.82/- 1.17 ± 5.39 mmHg (P = 0.0079 for systolic BP, P = 0.0415 for diastolic BP). Furthermore, the reduction in UACR after 24 weeks significantly correlated with an improvement in home BP profile, but not with changes in other variables, including office BP. Multivariate linear regression analysis also revealed that the change in morning home systolic BP was a significant contributor to the change in log-UACR. CONCLUSIONS: In Japanese patients with T2DM and diabetic nephropathy, dapagliflozin significantly improved albuminuria levels and the home BP profile. Improved morning home systolic BP was associated with albuminuria reduction. Trial registration The study is registered at the UMIN Clinical Trials Registry (UMIN000018930; http://www.umin.ac.jp/ctr/index-j.htm ). The study was conducted from July 1, 2015 to August 1, 2018.

    DOI： 10.1186/s12933-019-0912-3

    PubMed

    researchmap

  • A17586 Cardio-ankle vascular index predicts incidence of chronic kidney disease in patients with life-style related disease Reviewed

    Fumika Nishizawa, Yusuke Kobayashi, Hideo Kobayashi, Tetsuya Fujikawa, Tamio Iwamoto, Nobuhito Hirawa, Yoshiyuki Toya, Satoshi Umemura, Kouichi Tamura

    Journal of Hypertension   36   e251   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/01.hjh.0000549026.56437.42

    researchmap

  • A5669 Lower BMI despite of having abdominal obesity is a risk of sarcopenic obesity which shows high arterial stiffness in patients with life-style related disease Reviewed

    Shota Suzuki, Yusuke Kobayashi, Hideo Kobayashi, Tetsuya Fujikawa, Tamio Iwamoto, Nobuhito Hirawa, Yoshiyuki Toya, Satoshi Umemura, Kouichi Tamura

    Journal of Hypertension   36   e170   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/01.hjh.0000548693.27681.44

    researchmap

  • A14339 Impaired systolic blood pressure recovery after standing is associated with arterial stiffening and baroreceptor dysfunction in patients with life-style related disease Reviewed

    Ryutaro Morita, Yusuke Kobayashi, Hideo Kobayashi, Tetsuya Fujikawa, Tamio Iwamoto, Nobuhito Hirawa, Yoshiyuki Toya, Satoshi Umemura, Kouichi Tamura

    Journal of Hypertension   36   e228   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/01.hjh.0000548931.92288.07

    researchmap

  • Reduced secretion of parathyroid hormone and hypocalcemia in systemic heterozygous ATP2B1-null hypertensive mice Reviewed

    Yosuke Ehara, Nobuhito Hirawa, Kouichiro Sumida, Akira Fujiwara, Minako Kagimoto, Yuki Ooki-Okuyama, Megumi Fujita, Mari Katsumata, Yusuke Kobayashi, Sanae Saka, Ikuma Katou, Keisuke Yatsu, Satoshi Umemura, Kouichi Tamura

    Hypertension Research   41 ( 9 )   1 - 9   2018.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Nature Publishing Group  

    DOI： 10.1038/s41440-018-0067-8

    Scopus

    PubMed

    researchmap

  • Atherosclerosis of the carotid bulb is associated with the severity of orthostatic hypotension in non-diabetic adult patients: a cross-sectional study. Reviewed International journal

    Kobayashi Y, Ishiguro H, Fujikawa T, Kobayashi H, Sumida K, Kagimoto M, Okuyama Y, Ehara Y, Katsumata M, Fujita M, Fujiwara A, Saka S, Yatsu K, Hirawa N, Toya Y, Yasuda G, Umemura S, Tamura K

    Clinical and experimental hypertension (New York, N.Y. : 1993)   1 - 8   2018.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: The carotid bulb has a high density of baroreceptors that play an important role in maintaining blood pressure. We hypothesized that atherosclerosis of the carotid bulb would reflect the severity of orthostatic hypotension more accurately than would atherosclerosis of other carotid artery segments. METHODS: This cross-sectional study included 198 non-diabetic adults. We measured the cardio-vascular ankle index as an index of arterial stiffness, intima-media thickness in each carotid artery segment (internal carotid artery, carotid bulb, distal and proximal portions, respectively, of the common carotid artery) as a measure of atherosclerosis, and heart rate variability as a measure of cardiac autonomic function. The sit-to-stand test was used to assess severity of orthostatic hypotension. RESULTS: Intima-media thickness of the carotid bulb was correlated with orthostatic systolic blood pressure change (r = -0.218, p = 0.002), cardio-ankle vascular index (r = 0.365, p < 0.001) and heart rate variability parameters. Multivariate regression analysis revealed that among all of the segments, only intima-media thickness of the carotid bulb was an independent predictor of orthostatic systolic blood pressure change (p = 0.022). CONCLUSION: Atherosclerosis of the carotid bulb was associated with severity of orthostatic hypotension, arterial stiffening and cardiac autonomic dysfunction than that of other carotid artery segments.

    DOI： 10.1080/10641963.2018.1465073

    PubMed

    researchmap

  • The effects of anti-hypertensive drugs and the mechanism of hypertension in vascular smooth muscle cell-specific ATP2B1 knockout mice Reviewed

    Yuki Okuyama, Nobuhito Hirawa, Megumi Fujita, Akira Fujiwara, Yosuke Ehara, Keisuke Yatsu, Koichiro Sumida, Minako Kagimoto, Mari Katsumata, Yusuke Kobayashi, Sanae Saka, Satoshi Umemura, Kouichi Tamura

    Hypertension Research   41 ( 2 )   80 - 87   2018.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Nature Publishing Group  

    DOI： 10.1038/hr.2017.92

    Scopus

    PubMed

    researchmap

  • Monozygotic twins discordant for primary aldosteronism: a case report (vol 31, pg 754, 2017) Reviewed

    Y. Kobayashi, K. Yatsu, K. Nakata-Shimokihara, N. Inoue, T. Fujikawa, N. Hirawa, S. Umemura, F. Satoh, G. P. Rossi, K. Tamura

    JOURNAL OF HUMAN HYPERTENSION   31 ( 11 )   760 - 760   2017.11

    　More details

  • Monozygotic twins discordant for primary aldosteronism: a case report Reviewed

    Y. Kobayashi, K. Yatsu, K. Nakata-Shimokihara, N. Inoue, T. Fujikawa, N. Hirawa, S. Umemura, F. Satoh, G. P. Rossi, K. Tamura

    JOURNAL OF HUMAN HYPERTENSION   31 ( 11 )   754 - 755   2017.11

    　More details

  • Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure Reviewed

    Mari Katsumata, Nobuhito Hirawa, Koichiro Sumida, Minako Kagimoto, Yosuke Ehara, Yuki Okuyama, Megumi Fujita, Akira Fujiwara, Mayumi Kobayashi, Yusuke Kobayashi, Yuichiro Yamamoto, Sanae Saka, Keisuke Yatsu, Tetsuya Fujikawa, Yoshiyuki Toya, Gen Yasuda, Kouichi Tamura, Satoshi Umemura

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   21 ( 5 )   858 - 865   2017.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：SPRINGER  

    Tolvaptan, a vasopressin V-2 receptor blocker, has a diuretic effect for patients with heart failure. However, there were a few data concerning the effects of tolvaptan in patients with chronic kidney disease (CKD).
    We retrospectively analyzed 21 patients with chronic heart failure and CKD. Tolvaptan was co-administered with other diuretics in-use, every day. We compared clinical parameters before and after the treatments with tolvaptan. Furthermore, we examined the correlations between baseline data and the change of body weight.
    Tolvaptan decreased the body weight and increased the urine volume (p = 0.001). The urine osmolality significantly decreased throughout the study period. Urinary Na/Cr ratio and FENa changed significantly after 4 h, and more remarkable after 8 h (p = 0.003, both). Serum creatinine increased slightly after 1 week of treatment (p = 0.012). The alteration of body weight within the study period correlated negatively with the baseline urine osmolality (r = -0.479, p = 0.038), the baseline urine volume (r = -0.48, p = 0.028), and the baseline inferior vena cava diameter (IVCD) (r = -0.622, p = 0.017). Hyponatremia was improved to the normal value, and the augmentations of the sodium concentration were negatively associated with the basal sodium levels (p = 0.01, r = -0.546).
    Tolvaptan is effective in increasing diuresis and improved hyponatremia, even in patients with CKD. The baseline urine osmolality, urine volume, and IVCD may be useful predictors for diuretic effects of tolvaptan.

    DOI： 10.1007/s10157-016-1379-0

    Web of Science

    PubMed

    researchmap

  • Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Reviewed

    Katsumata M, Hirawa N, Sumida K, Kagimoto M, Ehara Y, Okuyama Y, Fujita M, Fujiwara A, Kobayashi M, Kobayashi Y, Yamamoto Y, Saka S, Yatsu K, Fujikawa T, Toya Y, Yasuda G, Tamura K, Umemura S

    Clin Exp Nephrol.   21 ( 5 )   858-865 - 865   2017.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：INT HEART JOURNAL ASSOC  

    BACKGROUND: Tolvaptan, a vasopressin V2 receptor blocker, has a diuretic effect for patients with heart failure. However, there were a few data concerning the effects of tolvaptan in patients with chronic kidney disease (CKD). METHODS: We retrospectively analyzed 21 patients with chronic heart failure and CKD. Tolvaptan was co-administered with other diuretics in-use, every day. We compared clinical parameters before and after the treatments with tolvaptan. Furthermore, we examined the correlations between baseline data and the change of body weight. RESULTS: Tolvaptan decreased the body weight and increased the urine volume (p = 0.001). The urine osmolality significantly decreased throughout the study period. Urinary Na/Cr ratio and FENa changed significantly after 4 h, and more remarkable after 8 h (p = 0.003, both). Serum creatinine increased slightly after 1 week of treatment (p = 0.012). The alteration of body weight within the study period correlated negatively with the baseline urine osmolality (r = -0.479, p = 0.038), the baseline urine volume (r = -0.48, p = 0.028), and the baseline inferior vena cava diameter (IVCD) (r = -0.622, p = 0.017). Hyponatremia was improved to the normal value, and the augmentations of the sodium concentration were negatively associated with the basal sodium levels (p = 0.01, r = -0.546). CONCLUSIONS: Tolvaptan is effective in increasing diuresis and improved hyponatremia, even in patients with CKD. The baseline urine osmolality, urine volume, and IVCD may be useful predictors for diuretic effects of tolvaptan.

    DOI： 10.1007/s10157-016-1379-0

    PubMed

    researchmap

  • Relationship between Arterial Stiffness and Blood Pressure Drop During the Sit-to-stand Test in Patients with Diabetes Mellitus Reviewed

    Yusuke Kobayashi, Tetsuya Fujikawa, Hideo Kobayashi, Koichiro Sumida, Shota Suzuki, Minako Kagimoto, Yuki Okuyama, Yosuke Ehara, Mari Katsumata, Megumi Fujita, Akira Fujiwara, Sanae Saka, Keisuke Yatsu, Tatsuo Hashimoto, Tadashi Kuji, Nobuhito Hirawa, Yoshiyuki Toya, Gen Yasuda, Satoshi Umemura

    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS   24 ( 2 )   147 - 156   2017

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.5551/jat.34645

    Web of Science

    PubMed

    researchmap

  • Effects of the oriental herbal medicine Bofu-tsusho-san in obesity hypertension: A multicenter, randomized, parallel-group controlled trial (ATH-D-14-01021.R2) Reviewed

    Kengo Azushima, Kouichi Tamura, Sona Haku, Hiromichi Wakui, Tomohiko Kanaoka, Masato Ohsawa, Kazushi Uneda, Ryu Kobayashi, Kohji Ohki, Toru Dejima, Akinobu Maeda, Tatsuo Hashimoto, Jin Oshikawa, Yusuke Kobayashi, Koichiro Nomura, Chieko Azushima, Yasuyo Takeshita, Ryota Fujino, Ken Uchida, Ken Shibuya, Daisaku Ando, Yasuo Tokita, Tetsuya Fujikawa, Yoshiyuki Toya, Satoshi Umemura

    ATHEROSCLEROSIS   240 ( 1 )   297 - 304   2015.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.atherosclerosis.2015.01.025

    Web of Science

    PubMed

    researchmap

  • Efficacy of cyclosporine combination therapy for new-onset minimal change nephrotic syndrome in adults Reviewed

    Akira Fujiwara, Nobuhito Hirawa, Yusuke Kobayashi, Keisuke Yatsu, Mari Katsumata, Yohsuke Ehara, Yuki Okuyama, Jun Yutoh, Tomoko Kaneda, Megumi Fujita, Yuichiro Yamamoto, Sanae Saka, Yoshiyuki Toya, Gen Yasuda, Satoshi Umemura

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   19 ( 2 )   240 - 246   2015.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10157-014-0975-0

    Web of Science

    PubMed

    researchmap

  • Impaired nitric oxide production and increased blood pressure in systemic heterozygous ATP2B1 null mice Reviewed

    Akira Fujiwara, Nobuhito Hirawa, Megumi Fujita, Yusuke Kobayashi, Yuki Okuyama, Keisuke Yatsu, Mari Katsumata, Yuichiro Yamamoto, Naoaki Ichihara, Sanae Saka, Yoshiyuki Toya, Gen Yasuda, Yoshio Goshima, Yasuharu Tabara, Tetsuro Miki, Hirotsugu Ueshima, Yoshihiro Ishikawa, Satoshi Umemura

    JOURNAL OF HYPERTENSION   32 ( 7 )   1415 - 1423   2014.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/HJH.0000000000000206

    Web of Science

    PubMed

    researchmap

  • Rituximab Treatment for Adult Purpura Nephritis with Nephrotic Syndrome Reviewed

    Hiroaki Ishiguro, Tatsuo Hashimoto, Mariko Akata, Shota Suzuki, Kengo Azushima, Yusuke Kobayashi, Tomohiko Kanaoka, Shinichiro Yoshida, Hiromichi Wakui, Jin Oshikawa, Kiyotaka Nagahama, Yoshiaki Inayama, Kouichi Tamura, Yoshiyuki Toya, Satoshi Umemura

    INTERNAL MEDICINE   52 ( 10 )   1079 - 1083   2013

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.2169/internalmedicine.52.9325

    Web of Science

    PubMed

    researchmap

  • Mice Lacking Hypertension Candidate Gene ATP2B1 in Vascular Smooth Muscle Cells Show Significant Blood Pressure Elevation Reviewed

    Yusuke Kobayashi, Nobuhito Hirawa, Yasuharu Tabara, Hidenori Muraoka, Megumi Fujita, Nobuko Miyazaki, Akira Fujiwara, Yasuhiro Ichikawa, Yuichiro Yamamoto, Naoaki Ichihara, Sanae Saka, Hiromichi Wakui, Shin-ichiro Yoshida, Keisuke Yatsu, Yoshiyuki Toya, Gen Yasuda, Katsuhiko Kohara, Yoshikuni Kita, Kohtaro Takei, Yoshio Goshima, Yoshihiro Ishikawa, Hirotsugu Ueshima, Tetsuro Miki, Satoshi Umemura

    HYPERTENSION   59 ( 4 )   854 - U213   2012.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1161/HYPERTENSIONAHA.110.165068

    Web of Science

    PubMed

    researchmap

  • Silent Brain Infarction and Rapid Decline of Kidney Function in Patients With CKD: A Prospective Cohort Study Reviewed

    Mayumi Kobayashi, Nobuhito Hirawa, Satoshi Morita, Keisuke Yatsu, Yusuke Kobayashi, Yuichiro Yamamoto, Sanae Saka, Yoshiyuki Toya, Gen Yasuda, Satoshi Umemura

    AMERICAN JOURNAL OF KIDNEY DISEASES   56 ( 3 )   468 - 476   2010.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1053/j.ajkd.2010.03.018

    Web of Science

    PubMed

    researchmap

  • Cardiac-Specific Activation of Angiotensin II Type 1 Receptor-Associated Protein Completely Suppresses Cardiac Hypertrophy in Chronic Angiotensin II-Infused Mice Reviewed

    Hiromichi Wakui, Kouichi Tamura, Yutaka Tanaka, Miyuki Matsuda, Yunzhe Bai, Toru Dejima, Shin-ichiro Masuda, Atsu-ichiro Shigenaga, Akinobu Maeda, Masaki Mogi, Naoaki Ichihara, Yusuke Kobayashi, Nobuhito Hirawa, Tomoaki Ishigami, Yoshiyuki Toya, Machiko Yabana, Masatsugu Horiuchi, Susumu Minamisawa, Satoshi Umemura

    HYPERTENSION   55 ( 5 )   1157 - U138   2010.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1161/HYPERTENSIONAHA.109.147207

    Web of Science

    PubMed

    researchmap

  • Relationship between silent brain infarction and chronic kidney disease Reviewed

    Mayumi Kobayashi, Nobuhito Hirawa, Keisuke Yatsu, Yusuke Kobayashi, Yuichiro Yamamoto, Sanae Saka, Daisaku Andoh, Yoshiyuki Toya, Gen Yasuda, Satoshi Umemura

    NEPHROLOGY DIALYSIS TRANSPLANTATION   24 ( 1 )   201 - 207   2009.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1093/ndt/gfn419

    Web of Science

    PubMed

    researchmap

▼display all

MISC

  • A SINGLE-CENTER, RETROSPECTIVE STUDY OF BLOOD PRESSURE EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE

    Rina Kawano, Nobuhito Hirawa, Aiko Haruna, Moe Ozawa, Tatsuya Haze, Shota Suzuki, Yuki Ohki, Yusuke Kobayashi, Akira Fujiwara, Sanae Saka, Kouichi Tamura

    JOURNAL OF HYPERTENSION   41   E416 - E416   2023.1

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • THE ASSOCIATION BETWEEN FRAILTY OR SARCOPENIA AND INTRADIALYTIC HYPOTENSION

    Moe Ozawa, Nobuhito Hirawa, Aiko Haruna, Tatsuya Haze, Rina Kawano, Shiro Komiya, Yuki Ohki, Yusuke Kobayashi, Akira Fujiwara, Sanae Saka, Masaaki Hanaoka, Hiroshi Mitsuhashi, Satoshi Yamaguchi, Toshimasa Ohnishi, Kouichi Tamura

    JOURNAL OF HYPERTENSION   41   E387 - E387   2023.1

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 新規止血剤ノブリードを使用する際のタイマーは平均3分

    柴田 和彦, 中井 滋, 新里 高弘, 小林 雄祐, 田村 功一

    日本透析医学会雑誌   54 ( Suppl.1 )   331 - 331   2021.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • Study of LPIN1 as a new candidate gene for essential hypertension

    藤原亮, 小澤萌枝, 角田剛一郎, 平和伸仁, 谷津圭介, 土師達也, 古宮士朗, 大城由紀, 小林雄祐, 涌井広道, 田村功一

    日本高血圧学会総会プログラム・抄録集(CD-ROM)   43rd   2021

    　More details

  • 原発性アルドステロン症の原因としての遺伝子変異 生殖細胞変異と体細胞変異、そして環境変化のthree-hit model

    小林 雄祐

    循環器内科   88 ( 3 )   312 - 317   2020.9

    　More details

    Language：Japanese   Publisher：(有)科学評論社  

    researchmap

  • ASSOCIATIONS BETWEEN CHANGES IN RENIN ACTIVITY AND ALDOSTERONE LEVELS AND CHANGES IN KIDNEY FUNCTION AFTER TREATMENT FOR PRIMARY ALDOSTERONISM: A LARGE MULTICENTER COHORT STUDY IN JAPAN

    Yusuke Kobayashi, Yuichiro Yano, Tatsuya Haze, Yu Hatano, Kouichi Tamura, Mitsuhide Naruse

    NEPHROLOGY DIALYSIS TRANSPLANTATION   35   514 - 514   2020.6

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • サブクリニカルクッシング症候群を合併した特発性アルドステロン症に対してコルチゾール産生腺腫側の副腎全摘摘除術を施行し、臨床経過が良好であった一例

    北地 大祐, 池上 充, 川崎 敬子, 大城 由紀, 青木 麻美, 江原 洋介, 小林 雄祐, 岩本 彩雄, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   8回   180 - 180   2019.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • ATP2B1遺伝子の一塩基多型は治療抵抗性高血圧と関連する

    小林 雄祐, 平和 伸仁, 土師 達也, 古宮 士朗, 角田 剛一郎, 鍵本 美奈子, 鈴木 将太, 大城 由紀, 江原 洋介, 藤原 亮, 坂 早苗, 谷津 圭介, 小林 英雄, 梅村 敏, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   8回   144 - 144   2019.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 摘出した副腎にコルチゾール産生腺腫と多数のアルドステロン産生細胞塊を認めた特発性アルドステロン症の1例

    池上 充, 小林 雄祐, 鈴木 真理恵, 花岡 正哲, 大城 由紀, 江原 洋介, 青木 麻美, 岩本 彩雄

    日本内科学会雑誌   108 ( 4 )   770 - 776   2019.4

    　More details

    Language：Japanese   Publisher：(一社)日本内科学会  

    researchmap

  • 原発性アルドステロン症 診断・治療の最前線 横浜市大関連施設におけるAVS症例をまとめた自験例解析からも見えてくる、PA診断の課題と今後の提案

    谷津 圭介, 小林 雄祐, 坂 早苗, 春原 須美玲, 涌井 広道, 平和 伸仁, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   7回   150 - 150   2018.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 原発性アルドステロン症 診断・治療の最前線 横浜市大関連施設におけるAVS症例をまとめた自験例解析からも見えてくる、PA診断の課題と今後の提案

    谷津 圭介, 小林 雄祐, 坂 早苗, 春原 須美玲, 涌井 広道, 平和 伸仁, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   7回   150 - 150   2018.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 摘出した副腎にコルチゾール産生腺腫と多数のアルドステロン産生細胞塊を認めた特発性アルドステロン症の1例

    池上 充, 小林 雄祐, 鈴木 真理恵, 花岡 正哲, 大城 由紀, 青木 麻美, 岩本 彩雄

    日本内科学会関東地方会   639回   45 - 45   2018.2

    　More details

    Language：Japanese   Publisher：日本内科学会-関東地方会  

    researchmap

  • 脂肪組織移植がLPIN1欠損マウスの血圧と糖脂質代謝に与える影響

    梅原 琴乃, 角田 剛一朗, 谷津 圭介, 江原 洋介, 大城 由紀, 藤田 恵美, 藤原 亮, 小林 雄祐, 平和 伸仁, 梅村 敏, 田村 功一

    日本高血圧学会総会プログラム・抄録集   40回   366 - 366   2017.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 【高血圧 高血圧学アップデート】 高血圧学の今とこれから

    矢崎 義雄, 下澤 達雄, 中村 敏子, 小林 雄祐

    Medical Practice   34 ( 8 )   1236 - 1254   2017.8

    　More details

    Language：Japanese   Publisher：(株)文光堂  

    researchmap

  • 中高年の生活習慣病患者において内臓脂肪型肥満を認めながらもBMI低値であることは動脈弾性低下、起立性低血圧のリスクである

    下木原 久美, 小林 雄祐, 小林 英雄, 藤川 哲也, 谷津 圭介, 平和 伸仁, 梅村 敏, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   6回   147 - 147   2017.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 治療に難渋したヘパリン起因性血小板減少症(HIT)合併ANCA関連血管炎患者の1例

    中田 久美, 小林 雄祐, 石黒 裕章, 井上 典子, 国保 敏晴, 田村 功一

    日本透析医学会雑誌   50 ( Suppl.1 )   698 - 698   2017.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 2度の大網巻絡解除術、CAPDからAPDへの移行を経て腹膜透析を継続できた一例

    井上 典子, 中田 久美, 石黒 裕章, 小林 雄祐, 国保 敏晴, 田村 功一

    日本透析医学会雑誌   50 ( Suppl.1 )   767 - 767   2017.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 治療抵抗性腹部大動脈瘤合併ネフローゼ症候群にLDLアフェレーシスを施行した一例

    国保 敏晴, 小林 雄祐, 石黒 裕章, 井上 典子, 中田 久美

    日本透析医学会雑誌   50 ( Suppl.1 )   646 - 646   2017.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • CAVIと短時間心拍変動解析を用いた起立性低血圧・高血圧の病態の差異の検討

    角田 剛一朗, 小林 雄祐, 小林 英雄, 藤川 哲也, 谷津 圭介, 平和 伸仁, 梅村 敏, 田村 功一

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   6回   162 - 162   2017.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 遷延する尿毒症症状を認め、治療条件に苦慮した1例

    長谷川 千尋, 佐々木 博章, 今井 隆二, 小林 雄祐, 国保 敏晴

    日本透析医学会雑誌   50 ( Suppl.1 )   853 - 853   2017.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 血管平滑筋特異的ATP2B1ノックアウトマウスはCaチャネル拮抗薬に対する薬剤応答性を認めた

    奥山 由紀, 角田 剛一郎, 鍵本 美奈子, 江原 洋介, 勝又 真理, 藤田 恵美, 藤原 亮, 小林 雄祐, 坂 早苗, 谷津 圭介, 梅村 敏, 平和 伸仁

    日本高血圧学会総会プログラム・抄録集   39回   339 - 339   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • ATP2B1血管平滑筋過剰発現マウスの作製と解析

    江原 洋介, 角田 剛一郎, 奥山 由紀, 藤田 恵美, 勝又 真理, 藤原 亮, 小林 雄祐, 坂 早苗, 谷津 圭介, 梅村 敏, 平和 伸仁

    日本高血圧学会総会プログラム・抄録集   39回   405 - 405   2016.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 軽度トランスアミナーゼの上昇により尿路悪性腫瘍の多発肝転移が発見された血液透析患者の一例

    国保 敏晴, 小林 雄祐, 石黒 裕章, 井上 典子, 海老原 正行

    日本透析医学会雑誌   49 ( Suppl.1 )   678 - 678   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 脂質異常症を合併する血液透析患者におけるEPA/DHA製剤投与によるABI改善効果の検討

    井上 典子, 小林 雄祐, 海老原 正行, 石黒 裕章, 國保 敏晴

    日本透析医学会雑誌   49 ( Suppl.1 )   670 - 670   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • n-3系多価不飽和脂肪酸投与による血液透析患者の動脈硬化改善および血圧変動性改善の有無の検討

    石渡 祐樹, 今井 隆二, 佐々木 博章, 小林 雄祐

    日本透析医学会雑誌   49 ( Suppl.1 )   829 - 829   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 血液透析中運動療法を実施した症例の心不全・急性冠症候群・感染症入院及び生命予後の2年間追跡調査 後方視的コホート研究

    井上 宜充, 沼田 純希, 田川 果歩, 飯倉 由季子, 小林 拓, 中村 明宏, 小林 雄祐, 国保 敏晴

    日本透析医学会雑誌   49 ( Suppl.1 )   849 - 849   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 血液透析患者における微小脳出血と動脈硬化指標の関連性 CAVIとbaPWVの比較検討

    小林 雄祐, 海老原 正行, 井上 典子, 石黒 裕章, 国保 敏晴, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   49 ( Suppl.1 )   451 - 451   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 生活習慣病患者においてCAVI高値は慢性腎臓病発症と関連する 2年間の前向き観察研究より

    小林 雄祐, 藤川 哲也, 小林 英雄, 梅村 敏

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   5回   193 - 193   2016.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 看護師の視点から見たカルニチン補充療法の効果

    中村 明宏, 小林 雄祐, 國保 敏晴

    日本透析医学会雑誌   49 ( Suppl.1 )   741 - 741   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 多発性嚢胞腎による血液透析患者に悪性リンパ腫を合併し診断に難渋した一例

    海老原 正行, 國保 敏晴, 小林 雄祐, 石黒 裕章, 井上 典子

    日本透析医学会雑誌   49 ( Suppl.1 )   596 - 596   2016.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 水疱性類天疱瘡を発症した血液透析患者の1例

    石黒 裕章, 国保 敏晴, 海老原 正行, 井上 典子, 岡田 和也, 小林 雄祐, 高瀬 奈緒, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   49 ( 1 )   59 - 64   2016.1

    　More details

  • 全身ヘテロATP2B1欠損マウスにおける高血圧と低Ca血症の関連について

    江原 洋介, 藤原 亮, 平和 伸仁, 角田 剛一郎, 奥山 由紀, 藤田 恵美, 勝又 真理, 小林 雄祐, 坂 早苗, 谷津 圭介, 戸谷 義幸, 安田 元, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   38回   374 - 374   2015.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 透析受容・拒否を繰り返した2症例

    国保 敏晴, 小林 雄祐, 石黒 裕章, 岡田 和也, 海老原 正行

    日本透析医学会雑誌   48 ( Suppl.1 )   877 - 877   2015.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 動脈硬化指標CAVIならびに自律神経機能指標としての心拍変動性と頸動脈の部位特異的IMTとの関連

    杉浦 康之, 小林 雄祐, 小林 英雄, 梅村 敏

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   4回   117 - 117   2015.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 動脈弾性指標CAVI高値と起立負荷時の心拍変動性低下はそれぞれ独立して起立時血圧低下を規定する

    小林 雄祐, 小林 英雄, 梅村 敏

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   4回   133 - 133   2015.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 水疱性類天疱瘡を発症した血液透析患者の一例

    石黒 裕章, 海老原 正行, 岡田 和也, 小林 雄祐, 国保 敏晴, 渡邊 憲, 中田 弘子, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   48 ( Suppl.1 )   727 - 727   2015.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 特発性血小板減少性紫斑病(ITP)に対してピロリ除菌療法が有効であった血液透析患者の一例

    岡田 和也, 国保 敏晴, 海老原 正行, 石黒 裕章, 小林 雄祐, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   48 ( Suppl.1 )   827 - 827   2015.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 慢性腎臓病患者における食の傾向と腎予後の関連性

    杉浦 康之, 小林 雄祐, 戸谷 元美, 竹本 悦子, 海老原 正行, 岡田 和也, 石黒 裕章, 国保 敏晴, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   48 ( Suppl.1 )   543 - 543   2015.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 血液透析患者におけるエイコサペンタエン酸(EPA)/アラキドン酸(AA)比と受診間(透析間)血圧変動性の関連性の検討

    海老原 正行, 小林 雄祐, 岡田 和也, 石黒 裕章, 国保 敏晴, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   48 ( Suppl.1 )   664 - 664   2015.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 血液透析患者におけるエイコサペンタエン酸(EPA)/アラキドン酸(AA)比は平均血圧とは独立して透析間血圧変動と関連する

    松本 峻, 小林 雄祐, 海老原 正行, 岡田 和也, 石黒 裕章, 国保 敏晴, 梅村 敏

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   4回   135 - 135   2015.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 高血圧感受性遺伝ATP2B1のノックアウトマウスを用いた解析 ATP2B1遺伝子の血管内皮における血圧への影響

    奥山 由紀, 藤原 亮, 平和 伸仁, 鍵本 美奈子, 江原 洋介, 勝又 真理, 藤田 恵美, 小林 雄祐, 坂 早苗, 谷津 圭介, 戸谷 義幸, 梅村 敏

    日本臨床分子医学会学術総会プログラム・抄録集   52回   77 - 77   2015.4

    　More details

    Language：Japanese   Publisher：日本臨床分子医学会  

    researchmap

  • 遠位尿細管特異的ATP2B1欠損マウスの食塩負荷による血圧変動について

    江原 洋介, 藤田 恵美, 平和 伸仁, 奥山 由紀, 勝又 真理, 藤原 亮, 坂 早苗, 小林 雄祐, 谷津 圭介, 戸谷 義幸, 安田 元, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   327 - 327   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • LPIN1欠損マウスを用いたLPIN1遺伝子の血圧の制御機能の解析

    奥山 由紀, 谷津 圭介, 江原 洋介, 勝又 真理, 藤田 恵美, 藤原 亮, 小林 雄祐, 坂 早苗, 平和 伸仁, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   406 - 406   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 長期にわたる遠位尿細管ATP2B1欠損がおよぼす影響 高齢マウスを用いた検討

    中山 雄太, 藤田 恵美, 平和 伸仁, 江原 洋介, 奥山 由紀, 勝又 真理, 藤原 亮, 小林 雄祐, 坂 早苗, 谷津 圭介, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   404 - 404   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 高血圧感受性遺伝子ATP2B1の遠位尿細管特異的欠損マウスの解析

    藤田 恵美, 平和 伸仁, 江原 洋介, 奥山 由紀, 勝又 真理, 藤原 亮, 小林 雄祐, 涌井 弘道, 坂 早苗, 谷津 圭介, 橋本 達夫, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   406 - 406   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 受診間血圧変動とCAVIならびに起立負荷時自律神経反応の関連性の検討

    小林 雄祐, 藤川 哲也, 小林 英雄, 奥山 由紀, 藤田 恵美, 藤原 亮, 坂 早苗, 谷津 圭介, 平和 伸仁, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   347 - 347   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • Ca transporter(MPCA1)をコードするATP2B1のSNP多型を用いたテーラーメード医療の可能性 GEANE研究サブスタディー

    谷津 圭介, 神出 計, 平和 伸仁, 奥山 由紀, 江原 洋介, 藤田 恵美, 藤原 亮, 小林 雄祐, 坂 早苗, 戸谷 義幸, 花田 裕典, 宮田 敏行, 河野 雄平, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   394 - 394   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • ATP2B1遺伝子の全身ヘテロノックアウトマウスにおける臓器障害とカルシウム代謝

    藤原 亮, 平和 伸仁, 江原 洋介, 奥山 由紀, 藤田 恵美, 勝又 真理, 小林 雄祐, 坂 早苗, 谷津 圭介, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   327 - 327   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 明日から役立つ高血圧関連疾患モデル研究 遺伝子解析からモデル動物での機能解析への戦略 ATP2B1遺伝子欠損マウス

    谷津 圭介, 平和 伸仁, 奥山 由紀, 江原 洋介, 藤田 恵美, 藤原 亮, 小林 雄祐, 坂 早苗, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   37回   263 - 263   2014.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 原発性胆汁性肝硬変(PBC)に合併した微小変化型ネフローゼ症候群(MCNS)の一例

    海老原 正行, 岡田 和也, 石黒 裕章, 小林 雄祐, 國保 敏晴

    日本腎臓学会誌   56 ( 6 )   870 - 870   2014.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 維持透析患者の特発性急性一型糖尿病の1症例

    安藤 匡人, 国保 敏晴, 小林 雄祐, 岡田 和也, 梅村 敏, 戸谷 義幸

    日本透析医学会雑誌   47 ( Suppl.1 )   571 - 571   2014.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 非糖尿病患者における腎機能と起立時血圧変化の関連性、そのメカニズムとしての自律神経機能の関与の検討

    東 裕勝, 小林 雄祐, 藤川 哲也, 奥山 由紀, 藤田 恵美, 藤原 亮, 坂 早苗, 谷津 圭介, 平和 伸仁, 戸谷 義幸, 小林 英雄, 梅村 敏

    日本腎臓学会誌   56 ( 3 )   397 - 397   2014.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 血液透析患者における無症候性微小脳出血と透析関連指標との関連性の評価

    小林 雄祐, 国保 敏晴, 安藤 匡人, 岡田 和也, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   47 ( Suppl.1 )   472 - 472   2014.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 起立性低血圧患者における動脈硬化指標CAVIと体位変換時の自律神経反応性の評価

    小林 雄祐, 小林 英雄

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   3回   128 - 128   2014.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 心不全を合併した高度腎不全症例へのトルバプタンの有効性と安全性

    岡田 和也, 安藤 匡人, 小林 雄祐, 国保 敏晴

    日本腎臓学会誌   56 ( 3 )   364 - 364   2014.5

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • DISTAL TUBULES-SPECIFIC KNOCKOUT OF ATP2B1 IS ASSOCIATED WITH SEVERE POLYURIA AND HYPERCALCIURIA WITHOUT HYPERTENSION

    Fujita Megumi, Hirawa Nobuhito, Okuyama Yuki, Fujiwara Akira, Kobayashi Yusuke, Saka Sanae, Yatsu Keisuke, Nagahama Kiyotaka, Umemura Satoshi

    NEPHROLOGY   19   34 - 34   2014.5

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 血液透析患者に発症しショック状態に陥った急性出血性直腸潰瘍の2症例

    国保 敏晴, 小林 雄祐, 岡田 和也, 安藤 匡人

    日本透析医学会雑誌   47 ( Suppl.1 )   840 - 840   2014.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 糖尿病性足壊疽による広義のMIA症候群に対しLカルニチンと特定積層型AN69膜の併用療法を施行した一例

    岡田 和也, 国保 敏晴, 安藤 匡人, 小林 雄祐, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   47 ( Suppl.1 )   975 - 975   2014.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 四肢麻痺を伴う低K血症が遷延化したアルコール依存症の1症例

    東 裕勝, 安藤 匡人, 岡田 和也, 小林 雄祐, 国保 敏晴

    日本内科学会関東地方会   601回   28 - 28   2013.11

    　More details

    Language：Japanese   Publisher：日本内科学会-関東地方会  

    researchmap

  • 脂質異常症症例におけるCAVIを用いた動脈硬化の進展程度評価とその関連因子の検討

    富田 啓人, 小林 雄祐, 藤川 哲也, 新居田 翔子, 奥山 由紀, 鈴木 将太, 藤田 恵美, 藤原 亮, 坂 早苗, 谷津 圭介, 橋本 達夫, 平和 伸仁, 戸谷 義幸, 小林 英雄, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   36回   367 - 367   2013.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 高血圧遺伝子研究の最先端 ゲノムワイド解析による高血圧関連遺伝子ATP2B1の発見と遺伝子改変マウスを用いた機能解析

    平和 伸仁, 小林 雄祐, 藤原 亮, 藤田 恵美, 奥山 由紀, 勝又 真理, 坂 早苗, 山本 有一郎, 谷津 圭介, 戸谷 義幸, 安田 元, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   36回   251 - 251   2013.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 起立性低血圧における動脈硬化指標CAVIと自律神経機能の関連の評価

    新居田 翔子, 小林 雄祐, 藤川 哲也, 小林 英雄, 富田 啓人, 奥山 由紀, 鈴木 将太, 藤田 恵美, 藤原 亮, 坂 早苗, 谷津 圭介, 橋本 達夫, 平和 伸仁, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   36回   301 - 301   2013.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • ATP2B1遺伝子の全身ヘテロノックアウトマウスにおける血圧上昇とNO産生の低下

    藤原 亮, 平和 伸仁, 奥山 由紀, 藤田 恵美, 小林 雄祐, 谷津 圭介, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   36回   334 - 334   2013.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • ブユによる虫刺症後にネフローゼ症候群を来した一例

    細川 由紀, 涌井 広道, 押川 仁, 鈴木 将太, 金岡 知彦, 小林 雄祐, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏, 長濱 清隆

    日本腎臓学会誌   55 ( 6 )   1043 - 1043   2013.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 高尿酸血症を有するCKD患者におけるフェブキソスタット/アロプリノールの効果 1年の無作為化比較試験

    平和 伸仁, 谷津 圭介, 勝又 真理, 松田 佳奈, 金口 翔, 奥山 由紀, 藤田 恵美, 藤原 亮, 山本 有一郎, 坂 早苗, 小林 雄祐, 戸谷 義幸, 安田 元, 梅村 敏

    日本腎臓学会誌   55 ( 6 )   1063 - 1063   2013.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 【血液透析患者の最適管理をめざして〜一般外来での対応】 血液透析患者の性機能・ホルモン異常

    小林 雄祐, 平和 伸仁

    診断と治療   101 ( 7 )   1065 - 1069   2013.7

    　More details

  • 血中アルドステロン高値を認めない治療抵抗性高血圧を呈した、片側性副腎微小腺腫による原発性アルドステロン症の一例

    鈴木 将太, 田村 功一, 有本 由紀, 小林 雄祐, 金岡 知彦, 涌井 広道, 押川 仁, 橋本 達夫, 久慈 直光, 戸谷 善幸, 槙山 和秀, 梅村 敏

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   2回   163 - 163   2013.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • ENHANCED AT1 RECEPTOR-ASSOCIATED PROTEIN IN RENAL TUBULE SUPPRESSES ANGIOTENSIN-MEDIATED HYPERTENSION

    Hiromichi Wakui, Kouichi Tamura, Shin-ichiro Masuda, Yuko Tsurumi-Ikeya, Megumi Fujita, Tomohiko Kanaoka, Tetsuya Fujikawa, Shota Suzuki, Yusuke Kobayashi, Machiko Yabana, Yoshiyuki Toya, Satoshi Umemura

    NEPHROLOGY DIALYSIS TRANSPLANTATION   28   329 - 329   2013.5

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 残存腎機能温存を目的とした無除水透析における無除水透析施行回数と透析前後収縮期血圧について

    矢花 眞知子, 涌井 広道, 鈴木 将太, 小林 雄祐, 前田 晃延, 坂 早苗, 押川 仁, 池谷 裕子, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   46 ( Suppl.1 )   759 - 759   2013.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 長期留置カテーテル関連感染症にテイコプラニンカテーテルロック法を用いた1例

    鈴木 将太, 小林 雄祐, 有本 由紀, 金岡 知彦, 涌井 広道, 押川 仁, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   46 ( Suppl.1 )   766 - 766   2013.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 透析患者に対して創部のヨードホルムガーゼの使用により、ヨードホルム中毒から心肺停止に至った一例

    細川 由紀, 涌井 広道, 押川 仁, 鈴木 将太, 金岡 知彦, 小林 雄祐, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   46 ( Suppl.1 )   640 - 640   2013.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 維持透析患者に対して術中血液濾過透析を施行した腹腔鏡下褐色細胞腫摘出術の一例

    涌井 広道, 大竹 慎二, 篠 みどり, 細川 由紀, 鈴木 将太, 小林 雄祐, 金岡 知彦, 押川 仁, 橋本 達夫, 田村 功一, 戸谷 義幸, 矢花 眞知子, 梅村 敏

    日本透析医学会雑誌   46 ( Suppl.1 )   753 - 753   2013.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • ネフローゼ症候群を合併したサブクリニカルクッシング症候群に対して腹腔鏡下右副腎腫瘍切除術を施行し、血圧と尿蛋白の著明な改善を認めた一例

    細川 由紀, 涌井 広道, 押川 仁, 鈴木 将太, 金岡 知彦, 小林 雄祐, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   2回   167 - 167   2013.5

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 腹膜透析施行中にエリスロポエチン中和活性陽性の赤芽球癆を発症した一例

    押川 仁, 有本 由紀, 鈴木 将太, 畝田 一司, 涌井 広道, 金岡 知彦, 小林 雄祐, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   46 ( Suppl.1 )   531 - 531   2013.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 新規自律神経解析ソフト「きりつ名人」を用いた、血液透析前後の自律神経機能変化の検討

    鈴木 将太, 小林 雄祐, 橋本 達夫, 有本 由紀, 中森 悠, 石黒 裕章, 金岡 知彦, 涌井 広道, 押川 仁, 田村 功一, 戸谷 義幸, 梅村 敏

    日本腎臓学会誌   55 ( 3 )   433 - 433   2013.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 高血圧感受性遺伝子ATP2B1の機能 遠位尿細管特異的ATP2B1欠損マウスを用いた検討

    藤田 恵美, 平和 伸仁, 奥山 由紀, 藤原 亮, 坂 早苗, 小林 雄祐, 涌井 広道, 橋本 達夫, 長濱 清隆, 山本 有一郎, 谷津 圭介, 梅村 敏

    日本腎臓学会誌   55 ( 3 )   398 - 398   2013.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 抑肝散により偽性アルドステロン症を来した1例

    有本 由紀, 涌井 広道, 押川 仁, 小林 雄祐, 金岡 知彦, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏

    日本内科学会関東地方会   593回   48 - 48   2012.12

    　More details

    Language：Japanese   Publisher：日本内科学会-関東地方会  

    researchmap

  • 炎症性腸疾患に対する血球成分除去療法の行方 潰瘍性大腸炎に対する白血球系細胞除去療法の効果と予後関連因子に関する検討

    平和 伸仁, 山本 有一郎, 谷津 圭介, 坂 早苗, 勝又 真理, 江原 洋介, 藤原 亮, 藤田 恵美, 小林 雄祐, 宮崎 喜子, 大木 美樹, 戸谷 義幸, 安田 元, 梅村 敏

    日本アフェレシス学会雑誌   31 ( Suppl. )   75 - 75   2012.11

    　More details

    Language：Japanese   Publisher：(一社)日本アフェレシス学会  

    researchmap

  • 新規高血圧感受性遺伝子ATP2B1は血管平滑筋において血圧調節と塩分感受性の重要な役割を担う

    小林 雄祐, 平和 伸仁, 藤田 恵美, 宮崎 喜子, 藤原 亮, 山本 有一郎, 坂 早苗, 谷津 圭介, 戸谷 義幸, 安田 元, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   35回   428 - 428   2012.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 腎臓における高血圧感受性遺伝子ATP2B1の解析 遠位尿細管特異的Atp2b1欠損マウスを用いた検討

    藤田 恵美, 平和 伸仁, 藤原 亮, 宮崎 喜子, 坂 早苗, 小林 雄祐, 一原 直昭, 山本 有一郎, 谷津 圭介, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   35回   427 - 427   2012.9

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 高尿酸血症を有するCKD患者に対するフェブキソスタットとアロプリノールの効果 6ヵ月の無作為比較試験

    平和 伸仁, 谷津 圭介, 山本 有一郎, 坂 早苗, 小林 雄祐, 藤原 亮, 藤田 恵美, 江原 洋介, 勝又 真理, 小林 麻裕美, 宮崎 喜子, 戸谷 義幸, 安田 元, 梅村 敏

    日本腎臓学会誌   54 ( 6 )   719 - 719   2012.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 【心腎連関の病態と治療の進歩-心臓と腎臓からみた循環器疾患】 治療薬解説 ACE阻害薬とARB

    小林 雄祐, 梅村 敏

    カレントテラピー   30 ( 8 )   827 - 832   2012.8

    　More details

    Language：Japanese   Publisher：(株)ライフメディコム  

    researchmap

  • トルバプタン併用が有効であった心不全合併腹膜透析患者の1例

    垣本 みどり, 柳 麻衣, 涌井 広道, 橋本 達夫, 畝田 一司, 小林 雄祐, 金岡 知彦, 押川 仁, 田村 功一, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   45 ( Suppl.1 )   689 - 689   2012.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 慢性腎臓病の急性増悪により発見され経皮経管的腎動脈拡張術(PTRA)にて維持透析を回避できた両側腎動脈狭窄症の一例

    金岡 知彦, 押川 仁, 畝田 一司, 重永 豊一郎, 小林 雄祐, 垣本 みどり, 吉田 伸一郎, 柳 麻衣, 涌井 広道, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   45 ( Suppl.1 )   808 - 808   2012.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 高マグネシウム血症によるCO2ナルコーシスを呈した高齢維持透析患者の一例

    橋本 達夫, 戸谷 義幸, 吉田 伸一郎, 小林 雄祐, 柳 麻衣, 金岡 知彦, 涌井 広道, 押川 仁, 石黒 裕章, 垣本 みどり, 畝田 一司, 田村 功一, 梅村 敏

    日本透析医学会雑誌   45 ( Suppl.1 )   819 - 819   2012.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • シスプラチンによるAKIの既往ある舌癌患者に対してシスプラチンの超選択的動注化学放射線療法に血液透析を連日併用し、AKIを回避することができた一症例

    小林 雄祐, 戸谷 義幸, 畝田 一司, 垣本 みどり, 金岡 知彦, 涌井 広道, 押川 仁, 橋本 達夫, 梅村 敏

    日本透析医学会雑誌   45 ( Suppl.1 )   777 - 777   2012.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 血液透析導入後10年間無除水透析を行えた1例

    矢花 眞知子, 涌井 弘道, 徳丸 由佳, 畝田 一司, 石黒 裕章, 藤田 恵美, 垣本 みどり, 小林 雄祐, 金岡 知彦, 山名 比早子, 押川 仁, 池谷 裕子, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   45 ( Suppl.1 )   782 - 782   2012.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 段階的腹膜透析導入(SMAP)による腹膜透析カテーテル皮下埋没期間中に鼠径ヘルニアを発症した一例

    涌井 広道, 三橋 洋, 押川 仁, 吉田 真一郎, 金岡 知彦, 柳 麻衣, 山田 裕貴子, 橋本 達夫, 小林 雄祐, 垣本 みどり, 畝田 一司, 田村 功一, 戸谷 義幸, 矢花 眞知子, 梅村 敏

    日本透析医学会雑誌   45 ( Suppl.1 )   704 - 704   2012.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 血漿交換療法が有効であったステロイド治療抵抗性視神経脊髄炎の10症例

    山名 比早子, 押川 仁, 畝田 一司, 石黒 裕章, 垣本 みどり, 小林 雄祐, 金岡 知彦, 柳 麻衣, 吉田 伸一郎, 涌井 広道, 橋本 達夫, 田村 功一, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   45 ( Suppl.1 )   639 - 639   2012.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 慢性腎臓病合併高血圧患者における血圧・心拍関連指標と腎臓機能障害の関連性についての検討

    金岡 知彦, 田村 功一, 大澤 正人, 涌井 広道, 小豆島 健護, 前田 晃延, 出島 徹, 白 善雅, 畝田 一司, 藤川 哲也, 小林 雄祐, 戸谷 義幸, 梅村 敏

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   1回   134 - 134   2012.4

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 両側性動脈硬化性腎動脈狭窄症に対するPTRAが腎血管性高血圧、虚血性腎症の改善に寄与した一例

    畝田 一司, 田村 功一, 垣本 みどり, 小林 雄祐, 金岡 知彦, 柳 麻衣, 吉田 伸一郎, 涌井 広道, 押川 仁, 橋本 達夫, 戸谷 義幸, 梅村 敏, 重永 豊一郎, 菅野 晃靖, 内野 和顕

    日本高血圧学会臨床高血圧フォーラムプログラム・抄録集   1回   156 - 156   2012.4

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 慢性腎臓病(CKD)に合併する高尿酸血症に対するフェブキソスタットとアロプリノールの比較

    平和 伸仁, 谷津 圭介, 山本 有一郎, 坂 早苗, 小林 雄祐, 藤原 亮, 藤田 恵美, 徳丸 由佳, 江原 洋介, 勝又 真理, 戸谷 義幸, 安田 元, 梅村 敏

    日本腎臓学会誌   54 ( 3 )   212 - 212   2012.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Delection of hypertension candidate gene ATP2B1 in vascular smooth muscle cells produces increased vascular contractile response and blood pressure elevation in mice.

    Y. Kobayashi, N. Hirawa, Y. Tabara, M. Fujita, N. Miyazaki, A. Fujiwara, Y. Yamamoto, N. Ichihara, S. Sake, H. Wakui, S. Yoshida, K. Yatsu, Y. Toda, G. Yasuda, K. Kohara, Y. Kita, H. Ueshima, T. Miki, S. Uemura

    ICC2012( ロンドン)   2012

    　More details

    Publishing type：Research paper, summary (international conference)  

    DOI： 10.1161/HYPERTENSIONAHA.110.165068

    researchmap

  • ヒト内臓脂肪組織における新規高血圧感受性遺伝子LPIN1を含む、各種遺伝子発現の検討

    宮崎 喜子, 谷津 圭介, 坂 早苗, 小林 雄祐, 藤原 亮, 藤田 恵美, 涌井 広道, 戸谷 義幸, 安田 元, 平和 伸仁, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   34回   566 - 566   2011.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • ゲノムワイド関連解析により同定された新規高血圧感受性遺伝子SMOC2の高感度酵母two-hybrid法による検討

    谷津 圭介, 江田 卓哉, 坂 早苗, 宮崎 喜子, 小林 雄祐, 藤原 亮, 藤田 恵美, 戸谷 義幸, 安田 元, 平和 伸仁, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   34回   566 - 566   2011.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • ゲノムワイド関連解析より同定された新規高血圧感受性遺伝子LPIN1のノックアウトマウスを用いた検討

    藤田 恵美, 谷津 圭介, 坂 早苗, 宮崎 喜子, 小林 雄祐, 藤原 亮, 涌井 広道, 戸谷 義幸, 安田 元, 平和 伸仁, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   34回   565 - 565   2011.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • IgA腎症感受性遺伝子のゲノムワイド探索から同定された候補遺伝子領域に対しepistasisの検討

    谷津 圭介, 坂 早苗, 岡 晃, 宮崎 喜子, 小林 雄祐, 藤原 亮, 藤田 恵美, 平和 伸仁, 猪子 英俊, 梅村 敏

    日本内分泌学会雑誌   87 ( 2 )   782 - 782   2011.9

    　More details

    Language：Japanese   Publisher：(一社)日本内分泌学会  

    researchmap

  • common diseaseに対しマイクロサテライトマーカーを用いたゲノムワイド関連解析の特徴

    谷津 圭介, 岡 晃, 坂 早苗, 宮崎 喜子, 小林 雄祐, 藤原 亮, 藤田 恵美, 平和 伸仁, 猪子 英俊, 梅村 敏

    日本内分泌学会雑誌   87 ( 2 )   782 - 782   2011.9

    　More details

    Language：Japanese   Publisher：(一社)日本内分泌学会  

    researchmap

  • 透析低血圧防止対策の実施による透析低血圧出現頻度の経過について

    矢花 眞知子, 涌井 広道, 藤田 恵美, 小林 雄祐, 牛尾 比早子, 金岡 知彦, 白 善雅, 吉田 伸一郎, 押川 仁, 田村 功一, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   44 ( Suppl.1 )   583 - 583   2011.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • APJ受容体の心・血管外作用 マウス劇症肝炎モデルにおける検討

    安崎 弘晃, 吉田 伸一郎, 橋本 達夫, 一原 直昭, 小林 雄祐, 石田 純治, 田村 功一, 石上 友章, 平和 伸仁, 戸谷 義幸, 川名 一朗, 深水 昭吉, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   33回   315 - 315   2010.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 微小変化型ネフローゼ症候群(MCNS)初期治療におけるシクロスポリン併用療法の有用性の検討 シクロスポリン併用は治療中の血圧に影響を与えるか

    藤原 亮, 平和 伸仁, 藤田 恵美, 宮崎 喜子, 小林 雄祐, 小林 麻裕美, 山本 有一郎, 坂 早苗, 谷津 圭介, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   33回   397 - 397   2010.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 酸化ストレスによって発現を亢進させるAPJ受容体の機能・反応性と分子機序

    吉田 伸一郎, 橋本 達夫, 安崎 弘晃, 木原 実, 野村 幸一郎, 波多 のぞみ, 石田 純治, 一原 直昭, 小林 雄祐, 田村 功一, 石上 友章, 平和 伸仁, 戸谷 義幸, 深水 昭吉, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   33回   315 - 315   2010.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • APJ受容体の動脈硬化増悪因子としての位置付け 酸化ストレス感受性分子としての重要性

    吉田 伸一郎, 橋本 達夫, 安崎 弘晃, 木原 実, 野村 幸一郎, 波多 のぞみ, 石田 純治, 一原 直昭, 小林 雄祐, 田村 功一, 石上 友章, 平和 伸仁, 戸谷 義幸, 深水 昭吉, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   33回   316 - 316   2010.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 新規高血圧感受性遺伝子ATP2B1の血管平滑筋特異的ノックアウトマウスを用いた検討

    小林 雄祐, 平和 伸仁, 藤田 恵美, 宮崎 喜子, 藤原 亮, 山本 有一郎, 坂 早苗, 吉田 伸一郎, 涌井 広道, 谷津 圭介, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   33回   250 - 250   2010.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 慢性腎臓病患者の腎予後に対する無症候性脳梗塞の意義

    小林 麻裕美, 平和 伸仁, 谷津 圭介, 小林 雄祐, 山本 有一郎, 坂 早苗, 田村 功一, 戸谷 義幸, 安田 元, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   32回   201 - 201   2009.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 酸化ストレス感受性受容体APJを介したangiotensin IIの動脈硬化病変形成作用

    吉田 伸一郎, 橋本 達夫, 安崎 弘晃, 木原 実, 野村 幸一郎, 今井 のぞみ, 石田 純治, 一原 直昭, 小林 雄祐, 田村 功一, 石上 友章, 平和 伸仁, 戸谷 義幸, 深水 昭吉, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   32回   172 - 172   2009.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 凝固障害疾患に合併した膜性腎症の一例

    小林 千夏, 平和 伸二, 垣本 みどり, 宮崎 喜子, 湯藤 潤, 藤原 亮, 小林 雄祐, 吉田 衝未, 金田 朋子, 小林 麻裕美, 山本 有一郎, 坂 早苗, 安藤 大作, 矢津 圭介, 安田 元, 梅村 敏

    日本腎臓学会誌   51 ( 6 )   683 - 683   2009.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • Dahl食塩感受性高血圧ラットに対するARBオルメサルタンの一過性投与による長期的な降圧効果について

    出島 徹, 田村 功一, 重永 豊一郎, 涌井 広道, 増田 真一朗, 東 公一, 一原 直昭, 小林 雄祐, 村田 みゆき, 梅村 敏

    日本腎臓学会誌   51 ( 3 )   308 - 308   2009.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • ゲノムワイド相関解析により同定した新規候補遺伝子SMOC-2の血圧値に与える影響の検討(QTL解析)

    谷津 圭介, 平和 伸仁, 小林 雄祐, 小林 麻裕美, 坂 早苗, 安田 元, 岡 晃, 猪子 英俊, 涌井 広道, 一原 直昭, 戸谷 義幸, 梅村 敏

    日本腎臓学会誌   51 ( 3 )   349 - 349   2009.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 新規動脈硬化症増悪因子であるAPJ受容体の酸化ストレスによる発現制御

    吉田 伸一郎, 橋本 達夫, 木原 実, 野村 幸一郎, 安崎 弘晃, 今井 のぞみ, 宮本 研, 一原 直昭, 小林 雄祐, 田村 功一, 石上 友章, 平和 伸仁, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   31回   179 - 179   2008.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 【どうみる?どうケアする?透析患者症状別対応ガイド】 症状から患者の体の変化を探ってみよう! ショック

    平和 伸仁, 小林 雄祐, 坂 早苗, 安藤 大作

    透析ケア   14 ( 9 )   889 - 893   2008.9

    　More details

  • SNP association analysis on the results of the genome-wide association mapping using microsatellite markers for essential hypertension

    K. Yatsu, N. Hirawa, Y. Kobayashi, M. Kobayashi, S. Saka, H. Wakui, T. Eda, N. Ichihara, D. Ando, M. Ogawa, Y. Toya, G. Yasuda, A. Oka, H. Inoko, S. Umemura

    JOURNAL OF HYPERTENSION   26   S148 - S148   2008.6

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • The relationships among G protein alfa z polypeptide, fatty liver and blood pressure

    N. Hirawa, M. Ogawa, T. Shiwa, M. Kobayashi, Y. Kobayashi, Y. Yamamoto, S. Saka, D. Andoh, K. Yatsu, Y. Tabara, Y. Toya, G. Yasuda, T. Miki, S. Umemura

    JOURNAL OF HYPERTENSION   26   S229 - S229   2008.6

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • The hemodynamics and metabolisms of lipocalin-type prostaglandin D2 synthase in rat

    N. Hirawa, Y. Uehara, T. Tsuchida, Y. Kobayashi, M. Kobayashi, T. Kaneda, S. Saka, D. Andoh, K. Yatsu, K. Seiki, G. Yasuda, Y. Urade, S. Umemura

    JOURNAL OF HYPERTENSION   26   S432 - S432   2008.6

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 透析日のみの不明熱を呈したリンパ節結核の一例

    安藤 大作, 安田 元, 小林 麻裕美, 金田 朋子, 小林 雄祐, 谷津 圭介, 平和 伸仁, 戸谷 義幸, 梅村 敏, 土橋 靖志, 大西 俊正

    日本透析医学会雑誌   41 ( Suppl.1 )   760 - 760   2008.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • Effects of azelnidipine on ambulatory blood pressure and autonomic nervous activity in hemodialysis patients

    G. Yasuda, Y. Kobayashi, M. Kobayashi, T. Kaneda, Y. Yamamoto, S. Saka, D. Ando, K. Yatsu, N. Hirawa, S. Umemura

    NEPHROLOGY   13   A69 - A69   2008.5

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 血圧・呼吸の制御 慢性腎炎における血清アルブミン値の24時間血圧への影響

    安藤 大作, 安田 元, 小林 雄祐, 小林 麻裕美, 金田 朋子, 坂 早苗, 谷津 圭介, 平和 伸仁, 戸谷 義幸, 梅村 敏

    循環制御   29 ( Suppl. )   63 - 63   2008.5

    　More details

    Language：Japanese   Publisher：日本循環制御医学会  

    researchmap

  • 維持腹膜透析患者の出口部感染にリネゾリド(ザイボツクス)が著効した一例

    金田 朋子, 安田 元, 安藤 大作, 平和 伸仁, 谷津 圭介, 小林 麻由美, 小林 雄祐, 戸谷 義幸, 梅村 敏

    日本透析医学会雑誌   41 ( Suppl.1 )   717 - 717   2008.5

    　More details

    Language：Japanese   Publisher：(一社)日本透析医学会  

    researchmap

  • 本態性高血圧症のQTL解析の結果と遺伝・環境因子相互作用の検討

    谷津 圭介, 平和 伸仁, 小林 雄祐, 金田 朋子, 小林 麻裕美, 坂 早苗, 安藤 大作, 安田 元, 岡 晃, 猪子 英俊, 涌井 広道, 戸谷 義幸, 梅村 敏

    日本腎臓学会誌   50 ( 3 )   336 - 336   2008.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 初発の微小変化型ネフローゼ症候群の初期治療におけるシクロスポリン併用効果の検討

    小林 雄祐, 平和 伸仁, 金田 朋子, 小林 麻裕美, 山本 有一郎, 坂 早苗, 安藤 大作, 谷津 圭介, 戸谷 義幸, 安田 元, 梅村 敏

    日本腎臓学会誌   50 ( 3 )   347 - 347   2008.4

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 2万個のマイクロサテライトマーカーを用いたゲノムワイド相関解析の結果明らかとなった本態性高血圧新規候補遺伝子のSNP関連解析

    谷津 圭介, 平和 伸仁, 小林 雄祐, 小林 麻裕美, 金田 朋子, 坂 早苗, 安藤 大作, 安田 元, 岡 晃, 猪子 英俊, 水木 信久, 涌井 広道, 江田 卓哉, 小川 桃子, 志和 忠志, 戸谷 義幸, 梅村 敏

    日本高血圧学会総会プログラム・抄録集   30回   221 - 221   2007.10

    　More details

    Language：Japanese   Publisher：(NPO)日本高血圧学会  

    researchmap

  • 妊娠を契機にネフローゼ症候群およびSLEを発症し、治療に難渋した一例

    玉澤 彰英, 谷津 圭介, 小林 雄祐, 小林 麻裕美, 金田 朋子, 坂 早苗, 安藤 大作, 小川 幸, 斉藤 圭介, 高橋 恒男, 安田 元, 戸谷 義幸, 梅村 敏, 平和 伸仁

    日本腎臓学会誌   49 ( 6 )   626 - 626   2007.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 急速な臨床経過を呈した軽鎖沈着症の1例

    徳永 麻裕美, 平和 伸仁, 小林 雄祐, 金田 朋子, 安藤 大作, 谷津 圭介, 村上 あゆみ, 佐々木 毅, 野澤 昭典, 安田 元, 梅村 敏

    日本腎臓学会誌   49 ( 6 )   610 - 610   2007.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • ステロイド治療および降圧治療により透析が回避された急速進行性糸球体腎炎(P-ANCA関連)の1症例

    坂 早苗, 平和 伸仁, 小林 雄祐, 金田 朋子, 小林 麻裕美, 山本 有一郎, 安藤 大作, 谷津 圭介, 遠藤 晃彦, 戸谷 義幸, 安田 元, 梅村 敏

    日本腎臓学会誌   49 ( 6 )   623 - 623   2007.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 臓器障害をほとんど認めない薬剤抵抗性の重症高血圧症の一例

    小林 雄祐, 平和 伸仁, 金田 朋子, 小林 麻裕美, 安藤 大作, 谷津 圭介, 宮島 栄治, 安田 元, 梅村 敏

    日本腎臓学会誌   49 ( 6 )   595 - 595   2007.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • IgA腎症疑いでフォローされていたが、腎生検でFabry病と診断された一例

    谷津 圭介, 平和 伸仁, 小林 雄祐, 小林 麻裕美, 金田 朋子, 坂 早苗, 安藤 大作, 安田 元, 戸谷 義幸, 梅村 敏

    日本腎臓学会誌   49 ( 6 )   600 - 600   2007.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

  • 不明熱を呈した腹膜透析患者の一例

    安藤 大作, 平和 伸仁, 金田 朋子, 小林 雄祐, 徳永 麻裕美, 谷津 圭介, 戸谷 義幸, 村上 あゆみ, 野澤 昭典, 上, 安田 元, 梅村 敏

    日本腎臓学会誌   49 ( 6 )   630 - 630   2007.8

    　More details

    Language：Japanese   Publisher：(一社)日本腎臓学会  

    researchmap

▼display all

Industrial property rights

  • 情報処理装置、情報処理方法、情報処理システム、及び情報処理プログラム

    大宮 康宏, 高野 毅, 遠藤 弘司, 岡田 興造, 小林 雄祐

    　More details

    Applicant：PST株式会社, 公立大学法人横浜市立大学

    Application no：特願2023-035091  Date applied：2023.3

    Announcement no：特開2023-178197  Date announced：2023.12

    J-GLOBAL

    researchmap

  • 情報処理装置、情報処理方法、情報処理システム、及び情報処理プログラム

    大宮 康宏, 高野 毅, 遠藤 弘司, 岡田 興造, 小林 雄祐

    　More details

    Applicant：PST株式会社, 公立大学法人横浜市立大学

    Application no：JP2022022687  Date applied：2022.6

    Patent/Registration no：特許第7246664号  Date registered：2023.3 

    J-GLOBAL

    researchmap

Awards

  • Young Clinician Award (YCA) 優秀賞

    2019   第8回 臨床高血圧フォーラム  

    小林 雄祐

    　More details

  • ISH New Investigator Committee Poster Presentation Award

    2017   第13回 アジア太平洋高血圧学会  

    小林 雄祐

    　More details

  • Austin Doyle Award, Travel Grant Award

    2016   第26回 国際高血圧学会  

    小林 雄祐

    　More details

  • 実地医療優秀賞

    2014   第3回 臨床高血圧フォーラム  

    小林 雄祐

    　More details

  • 優秀賞

    2012   第10回 腎と高血圧Update  

    小林 雄祐

    　More details

  • 同門会賞 Young Investigator's Award (YIA)

    2012   第3回 横浜市立大学第二内科  

    小林 雄祐

    　More details

  • Travel Grant Award

    2011   第21回 欧州高血圧学会  

    小林 雄祐

    　More details

▼display all

Research Projects

  • 若者の生きづらさを解消し高いウェルビーイングを実現するメタケアシティ共創拠点

    2022.11

    国立研究開発法人科学技術振興機構(JST)  共創の場形成支援プログラム(COI-NEXT)」共創分野本格型 

    　 More details

    Authorship：Coinvestigator(s) 

    researchmap

  • 多機関共同のリアルワールドデータ研究に対するrisk based approachを用いた臨床研究支援の実装と課題解決法の提案

    Grant number：22723796  2022.10 - 2023.3

    国立研究開発法人 日本医療研究開発機構（AMED）  研究開発推進ネットワーク事業 RBAの実装に向けた整備、方策等の提案及び推進

    田野島玲大, 熊谷雄治, 矢野裕一朗, 清水沙友里, ⾦⼦惇, 前⽥愼, 宮城悦子, ⼩林雄祐, 須江聡⼀郎, ⾼瀬創, 仁⽥学, ⼟師達也, 野﨑昭⼈, 岡田興造, 稲垣尚⼦

    　 More details

  • Elucidation of the pathophysiology of the direct association between the hypertension susceptibility gene ATP2B1 and atherosclerosis, and development of therapeutic strategies

    Grant number：19K17610  2019.4 - 2022.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

    KOBAYASHI Yusuke

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    Grant amount：\4290000 （ Direct Cost: \3300000 、 Indirect Cost：\990000 ）

    Using DNA extracted from oral mucosal cells in 1124 patients undergoing treatment for lifestyle-related diseases, we typed 12 SNPs, including rs11105378, among SNPs in the ATP2B1 gene, and found that the ATP2B1 gene is associated with treatment-resistant hypertension in Japanese lifestyle-related disease patients This is the first demonstration that the ATP2B1 gene is associated with treatment-resistant hypertension in Japanese patients with lifestyle-related diseases.In order to implement the results of this study into clinical practice as a method of tailor-made medicine for the prevention of atherosclerosis, we are analyzing the huge amount of data obtained through this study using evolutionary machine learning. In addition, by establishing a system of collaboration with research support organizations, we were able to build a system that enables us to consider exit strategies for social implementation of the results of this research as a predictive model for arteriosclerosis.

    researchmap

  • Analysis of new candidate genes for essential hypertension: ATP2B1 gene and LPIN1 gene

    Grant number：25293196  2013.4 - 2016.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)  Grant-in-Aid for Scientific Research (B)

    UMEMURA Satoshi, MIZUKI Nobuhisa, HIRAWA Nobuhito, OKA Akira, YATSU Keisuke, KOBAYASHI Yusuke

    　 More details

    Grant type：Competitive

    Grant amount：\18330000 （ Direct Cost: \14100000 、 Indirect Cost：\4230000 ）

    We have made four tissue specific ATP2B1 KO mice and overexpression ATP2B1 mice for these 3 years.Then, we reported the paper "Impaired nitric oxide production and increased blood pressure in systemic heterozygous ATP2B1 null mice."(J Hypertens. 2014 Jul;32(7):1415-23).
    LPIN1 gene is a key regulator of circadian rhythm for blood pressure control. Now, we are making preparation for submitting these data as the first report of key regulator of circadian rhythm for blood pressure control.

    researchmap